Acute promyelocytic leukemia: from highly fatal to high

Blood

111, 2505-2515

DOI: 10.1182/blood-2007-07-102798

Citation Report

#	Article	IF	Citations
1	Lymph nodes, bone marrow, and immunodeficiencies. , 2000, , 228-274.		1
4	Globalization of treatment strategies in leukemia: challenges and responsibilities. Leukemia, 2008, 22, 1093-1094.	3.3	1
5	Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nature Medicine, 2008, 14, 1333-1342.	15.2	325
6	Role of nuclear bodies in apoptosis signalling. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 2185-2194.	1.9	71
7	Chromosomal Abnormalities in Cancer. New England Journal of Medicine, 2008, 359, 722-734.	13.9	188
8	Biomedical science and technology in China. Lancet, The, 2008, 372, 1441-1443.	6.3	7
9	Acute promyelocytic leukemia with t(15;17): frequency of additional clonal chromosome abnormalities and FLT3 mutations. Leukemia and Lymphoma, 2008, 49, 2387-2389.	0.6	16
10	Genetic variations associated with interindividual sensitivity in the response to arsenic exposure. Pharmacogenomics, 2008, 9, 1113-1132.	0.6	76
11	Targeting p53 to mitochondria for cancer therapy. Cell Cycle, 2008, 7, 1949-1955.	1.3	110
12	Diagnosing Disseminated Intravascular Coagulopathy in Acute Promyelocytic Leukemia. Clinical Journal of Oncology Nursing, 2008, 12, 717-720.	0.3	3
13	Therapeutic potential of nuclear receptors. Expert Opinion on Therapeutic Patents, 2008, 18, 861-888.	2.4	13
14	New therapeutic approaches to acute myeloid leukemia. Expert Opinion on Drug Discovery, 2008, 3, 689-706.	2.5	3
15	Chromosomal translocations: revisited yet again. Blood, 2008, 112, 2183-2189.	0.6	127
16	Society of Internal Medicine, 2008, 97, 2093-2097.	0.0	0
17	Transcriptome and Proteome Analyses of Drug Interactions with Natural Products. Current Drug Metabolism, 2008, 9, 1038-1048.	0.7	18
18	The Effects of Ultrasound and Arsenic Trioxide on Neurogliocytoma Cells and Secondary Activation of Macrophages. Tumori, 2009, 95, 780-788.	0.6	5
19	CaracterÃsticas genÃ©ticas da leucemia promielocÃtica aguda de novo. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, 454-462.	0.7	1
20	Treatment strategies for pediatric acute myeloid leukemia. Expert Opinion on Pharmacotherapy, 2009, 10, 57-79.	0.9	12

#	Article	IF	Citations
21	Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3342-3347.	3.3	380
22	Reactive Oxygen Species Are Not Required for an Arsenic Trioxide-induced Antioxidant Response or Apoptosis. Journal of Biological Chemistry, 2009, 284, 12886-12895.	1.6	34
23	Induction of Metallothionein I by Arsenic via Metal-activated Transcription Factor 1. Journal of Biological Chemistry, 2009, 284, 12609-12621.	1.6	52
24	Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities. Antioxidants and Redox Signaling, 2009, 11, 3013-3069.	2.5	409
25	Inhibition of the Peptidyl-Prolyl-Isomerase Pin1 Enhances the Responses of Acute Myeloid Leukemia Cells to Retinoic Acid via Stabilization of RARÎ± and PML-RARÎ±. Cancer Research, 2009, 69, 1016-1026.	0.4	57
26	Use of All-trans Retinoic Acid in Combination with Arsenic Trioxide for Remission Induction in Patients with Newly Diagnosed Acute Promyelocytic Leukemia and for Consolidation/Maintenance in CR Patients. Acta Haematologica, 2009, 121, 1-8.	0.7	47
27	Arsenic Trioxide in a Hemodialytic Patient with Acute Promyelocytic Leukemia. Acta Haematologica, 2009, 122, 52-53.	0.7	14
29	Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience. Journal of Clinical Oncology, 2009, 27, 2668-2676.	0.8	90
30	Towards Retinoid Therapy for Alzheimers Disease. Current Alzheimer Research, 2009, 6, 302-311.	0.7	80
31	Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. Journal of Clinical Oncology, 2009, 27, 504-510.	0.8	355
32	Arsenic Toxicity to Saccharomyces cerevisiae Is a Consequence of Inhibition of the TORC1 Kinase Combined with a Chronic Stress Response. Molecular Biology of the Cell, 2009, 20, 1048-1057.	0.9	34
33	A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3378-3383.	3.3	114
34	Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure. Clinical Cancer Research, 2009, 15, 6321-6326.	3.2	91
35	Differentiation therapy of acute myeloid leukemia: past, present and future. Current Opinion in Hematology, 2009, 16, 84-91.	1.2	147
36	Encapsulation of the synthetic retinoids Am80 and LE540 into polymeric micelles and the retinoids' release control. Journal of Controlled Release, 2009, 136, 187-195.	4.8	39
37	Modulation of PML protein expression regulates JCV infection. Virology, 2009, 390, 279-288.	1.1	21
38	Nargenicin enhances 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced leukemia cell differentiation via PKCÎ²I/MAPK pathways. Biochemical Pharmacology, 2009, 77, 1694-1701.	2.0	23
39	Raf-1 Addiction in Ras-Induced Skin Carcinogenesis. Cancer Cell, 2009, 16, 149-160.	7.7	99

#	Article	IF	Citations
40	Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia. American Journal of Hematology, 2009, 84, 715-719.	2.0	23
41	Downregulation of the câ€MYC target gene, peroxiredoxin III, contributes to arsenic trioxideâ€induced apoptosis in acute promyelocytic leukemia. International Journal of Cancer, 2009, 125, 264-275.	2.3	22
42	Risk score for outcome after allogeneic hematopoietic stem cell transplantation. Cancer, 2009, 115, 4715-4726.	2.0	337
44	Coencapsulation of Arsenicâ€•and Platinumâ€based Drugs for Targeted Cancer Treatment. Angewandte Chemie - International Edition, 2009, 48, 9295-9299.	7.2	69
45	Effect of conjugates of all-trans-retinoic acid and shorter polyene chain analogues with amino acids on prostate cancer cell growth. European Journal of Medicinal Chemistry, 2009, 44, 3175-3187.	2.6	11
46	Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. International Journal of Hematology, 2009, 89, 489-496.	0.7	50
47	The Efficient Generation of Immunocompetent Dendritic Cells from Leukemic Blasts in Acute Myeloid Leukemia: A Local Experience. Pathology and Oncology Research, 2009, 15, 257-267.	0.9	2
48	Tailoring treatment strategy for acute promyelocytic leukemia in lowâ€income countries. Pediatric Blood and Cancer, 2009, 53, 303-305.	0.8	4
49	Vâ€PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenicâ€induced toxicity. Cancer Science, 2009, 100, 382-388.	1.7	11
50	An additional role for SUMO in ubiquitin-mediated proteolysis. Nature Reviews Molecular Cell Biology, 2009, 10, 564-568.	16.1	231
51	PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage. Oncogene, 2009, 28, 698-708.	2.6	37
52	Determination of 6-benzylthioinosine in mouse and human plasma by liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3871-3877.	1.2	1
53	Metabolites of acute promyelocytic leukemia cells participate in contributing to hypertriglyceridemia induced by all-trans retinoic acid. Leukemia Research, 2009, 33, 592-594.	0.4	5
54	Arsenic(III) Species Inhibit Oxidative Protein Folding in Vitro. Biochemistry, 2009, 48, 424-432.	1.2	82
55	Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. International Journal of Biochemistry and Cell Biology, 2009, 41, 16-20.	1.2	19
56	Arsenite medicinal use, metabolism, pharmacokinetics and monitoring in human hair. Biochimie, 2009, 91, 1260-1267.	1.3	39
57	Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Letters, 2009, 280, 134-144.	3.2	98
58	All-trans retinoic acid induces Thrombospondin-1 expression in acute promyelocytic leukemia cells though down-regulation of its transcription repressor, c-MYC oncoprotein. Biochemical and Biophysical Research Communications, 2009, 382, 790-794.	1.0	4

#	Article	IF	Citations
59	Deamino-hydroxy-phoslactomycin B, a biosynthetic precursor of phoslactomycin, induces myeloid differentiation in HL-60 cells. Biochemical and Biophysical Research Communications, 2009, 383, 406-410.	1.0	15
60	Anti-cancer drugs interfere with intracellular calcium signaling. NeuroToxicology, 2009, 30, 803-810.	1.4	75
61	Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias. Journal of Hematology and Oncology, 2009, 2, 51.	6.9	11
62	Chromosomes in Leukemia and Beyond: From Irrelevant to Central Players. Annual Review of Genomics and Human Genetics, 2009, 10, 1-18.	2.5	16
64	Acute Leukemia with M3 Morphology Without Cytogenetic Abnormalities Related to Acute Promyelocytic Leukemia: Description of a Refractory Pediatric Case. Clinical Leukemia, 2009, 3, E27-E30.	0.2	0
65	Management of Acquired Bleeding Problems in Cancer Patients. Emergency Medicine Clinics of North America, 2009, 27, 423-444.	0.5	6
66	How I treat acute promyelocytic leukemia. Blood, 2009, 114, 5126-5135.	0.6	228
67	Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Molecular Cancer Therapeutics, 2009, 8, 1955-1963.	1.9	150
68	Stem cell transplants for patients with relapsed/refractory leukaemia. Current Opinion in Hematology, 2009, 16, 444-452.	1.2	7
69	Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis. Blood, 2009, 113, 3172-3181.	0.6	47
70	RARÎ±2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood, 2009, 114, 600-607.	0.6	20
71	Differentiation therapy of leukemia: 3 decades of development. Blood, 2009, 113, 3655-3665.	0.6	295
72	Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood, 2009, 114, 5512-5521.	0.6	98
73	Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood, 2009, 113, 412-421.	0.6	97
75	Tumor Initiating Cells. Current Pharmaceutical Biotechnology, 2009, 10, 192-196.	0.9	24
76	Heat Shock Protein 90 â€“ a Potential Target in the Treatment of Human Acute Myelogenous Leukemia. Current Cancer Drug Targets, 2009, 9, 761-776.	0.8	52
77	Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System. CNS and Neurological Disorders - Drug Targets, 2009, 8, 387-392.	0.8	3
78	Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood, 2010, 115, 1697-1702.	0.6	107

#	Article	IF	Citations
79	The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood, 2010, 115, 948-956.	0.6	105
80	BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood, 2010, 116, 4274-4283.	0.6	131
81	Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells. Blood, 2010, 116, e26-e34.	0.6	76
82	Massive Ascites Associated with All-trans Retinoic Acid Treatment in Therapy-Related Acute Promyelocytic Leukemia. Internal Medicine, 2010, 49, 457-460.	0.3	4
83	Oxidative stress enhances granulocytic differentiation in HL 60 cells, an acute promyelocytic leukemia cell line. Free Radical Research, 2010, 44, 1328-1337.	1.5	10
84	Characteristics of Leukemia Stem Cells of Murine Myeloproliferative Disease Involving the Liver. Bulletin of Experimental Biology and Medicine, 2010, 149, 293-297.	0.3	1
85	Interaction of SDF-1Î± and CXCR4 plays an important role in pulmonary cellular infiltration in differentiation syndrome. International Journal of Hematology, 2010, 91, 293-302.	0.7	13
86	Relapsed APL patient with variant NPMâ€“RARÎ± fusion responded to arsenic trioxide-based therapy and achieved long-term survival. International Journal of Hematology, 2010, 91, 708-710.	0.7	14
87	Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience. International Journal of Hematology, 2010, 91, 820-825.	0.7	12
88	Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. International Journal of Hematology, 2010, 91, 742-747.	0.7	39
89	Investigation of anti-leukemia molecular mechanism of ITR-284, a carboxamide analog, in leukemia cells and its effects in WEHI-3 leukemia mice. Biochemical Pharmacology, 2010, 79, 389-398.	2.0	18
90	Acute promyelocytic leukemia occurring in a previously healthy bone marrow donor. Cancer Genetics and Cytogenetics, 2010, 200, 191-193.	1.0	0
91	PML-RARÎ±/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell, 2010, 17, 173-185.	7.7	276
92	PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and Gliomas. Cancer Cell, 2010, 17, 497-509.	7.7	224
93	PML/RARA Oxidation and Arsenic Binding Initiate the Antileukemia Response of As2O3. Cancer Cell, 2010, 18, 88-98.	7.7	301
94	Text mining for traditional Chinese medical knowledge discovery: A survey. Journal of Biomedical Informatics, 2010, 43, 650-660.	2.5	104
95	Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody. Cancer, 2010, 116, 369-376.	2.0	45
96	A common variant in the Von Willebrand factor gene is associated with multiple functional consequences. American Journal of Hematology, 2010, 85, 971-973.	2.0	4

#	Article	IF	Citations
97	Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. American Journal of Hematology, 2010, 85, 956-957.	2.0	16
98	Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. American Journal of Hematology, 2010, 85, 960-963.	2.0	13
99	Characterization of mitochondrial ferritinâ€deficient mice. American Journal of Hematology, 2010, 85, 958-960.	2.0	19
100	Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy. American Journal of Hematology, 2010, 85, 963-967.	2.0	6
101	Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. American Journal of Hematology, 2010, 85, 967-971.	2.0	19
106	Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: A systematic review. Leukemia Research, 2010, 34, 831-836.	0.4	95
107	ATRA is effective to an acute promyelocytic leukemia patient without RARA gene rearrangement. Leukemia Research, 2010, 34, e190-e193.	0.4	5
108	Arsenic trioxide â€" An old drug rediscovered. Blood Reviews, 2010, 24, 191-199.	2.8	244
109	Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia. Journal of Thrombosis and Haemostasis, 2010, 8, 773-782.	1.9	51
110	Epigallocatechinâ€3â€gallate induces cell death in acute myeloid leukaemia cells and supports allâ€trans retinoic acidâ€induced neutrophil differentiation via deathâ€associated protein kinase 2. British Journal of Haematology, 2010, 149, 55-64.	1.2	76
111	Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. British Journal of Haematology, 2010, 149, 399-409.	1.2	52
112	Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. British Journal of Haematology, 2010, 151, 209-220.	1.2	44
113	Strategy to further increase of cure rate in acute promyelocytic leukaemia: lowâ€dose allâ€trans retinoic acid and sequential maintenance cycle. British Journal of Haematology, 2010, 151, 406-409.	1.2	1
114	A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia. Leukemia, 2010, 24, 1265-1275.	3.3	21
115	Leukaemogenesis: more than mutant genes. Nature Reviews Cancer, 2010, 10, 23-36.	12.8	286
116	Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nature Reviews Cancer, 2010, 10, 775-783.	12.8	420
117	Arsenic toxicity in pathogenic Staphylococcus epidermidis and Klebsiella pneumoniae. International Journal of Biology, 2010, 2, .	0.1	5
118	Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH2 Terminal Kinase Activation and PTEN Upregulation. Clinical Cancer Research, 2010, 16, 4382-4391.	3.2	49

#	Article	IF	Citations
119	Distinct roles for miRâ€1 and miRâ€133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB Journal, 2010, 24, 3427-3437.	0.2	118
120	Isolated Bowel Relapse in Acute Promyelocytic Leukemia: An Unusual Site of Extramedullary Recurrence. Journal of Clinical Oncology, 2010, 28, e550-e553.	0.8	11
121	Critical Cysteine Residues of Kelch-Like ECH-Associated Protein 1 in Arsenic Sensing and Suppression of Nuclear Factor Erythroid 2-Related Factor 2. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 66-75.	1.3	63
122	Fragmentation of Human Erythrocyte Actin following Exposure to Hypoxia. Acta Haematologica, 2010, 123, 6-13.	0.7	6
123	A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment. Cardiovascular & Hematological Disorders Drug Targets, 2010, 10, 1-6.	0.2	4
124	Arsenic-Induced SUMO-Dependent Recruitment of RNF4 into PML Nuclear Bodies. Molecular Biology of the Cell, 2010, 21, 4227-4239.	0.9	63
125	Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5499-5510.	3.2	71
126	Cytotoxic effect of trans-cinnamaldehyde on human leukemia K562 cells. Acta Pharmacologica Sinica, 2010, 31, 861-866.	2.8	48
127	Curcumin Stimulates Reactive Oxygen Species Production and Potentiates Apoptosis Induction by the Antitumor Drugs Arsenic Trioxide and Lonidamine in Human Myeloid Leukemia Cell Lines. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 114-123.	1.3	79
128	Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. Journal of Experimental Medicine, 2010, 207, 731-750.	4.2	169
129	Acute Promyelocytic Leukemia: An Overview With Implications for Oncology Nurses. Clinical Journal of Oncology Nursing, 2010, 14, 747-759.	0.3	5
130	Interstitial insertion ofRARÎ±gene intoPMLgene in a patient with acute promyelocytic leukemia (APL) lacking the classic t(15;17). Hematology, 2010, 15, 332-337.	0.7	8
131	Role of Microparticles in the Hemostatic Dysfunction in Acute Promyelocytic Leukemia. Seminars in Thrombosis and Hemostasis, 2010, 36, 917-924.	1.5	49
132	Management of Acquired Bleeding Problems in Cancer Patients. Hematology/Oncology Clinics of North America, 2010, 24, 603-624.	0.9	2
133	Cytogenomics of cancers: From chromosome to sequence. Molecular Oncology, 2010, 4, 309-322.	2.1	23
134	Treatment of Patients With Acute Promyelocytic Leukemia: A Consensus Statement on Risk-Adapted Approaches to Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S122-S126.	0.2	10
135	Utilization of Molecular Phenotypes to Detect Relapse and Optimize the Management of Acute Promyelocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S139-S143.	0.2	0
136	Arsenic trioxide as an anti-tumour agent: mechanisms of action and strategies of sensitization. Journal of Applied Biomedicine, 2010, 8, 199-208.	0.6	12

#	Article	IF	Citations
137	Arsenic Trioxide Controls the Fate of the PML-RARÎ± Oncoprotein by Directly Binding PML. Science, 2010, 328, 240-243.	6.0	690
138	Mass Spectrometry-Based Identification of Y745 of Vav1 as a Tyrosine Residue Crucial in Maturation of Acute Promyelocytic Leukemia-Derived Cells. Journal of Proteome Research, 2010, 9, 752-760.	1.8	10
139	Mouse Models of Myeloid Leukemia. , 2010, , 597-610.		0
141	Thromboembolic and bleeding complications in acute leukemia. Expert Review of Hematology, 2010, 3, 719-730.	1.0	17
142	Cancerous stem cells: deviant stem cells with cancer-causing misbehavior. Stem Cell Research and Therapy, 2010, 1, 13.	2.4	19
143	Clinical proteomics of myeloid leukemia. Genome Medicine, 2010, 2, 41.	3.6	13
144	Acute promyelocytic leukemia: what are the treatment options?. Expert Opinion on Pharmacotherapy, 2010, 11, 587-596.	0.9	16
145	Treatment of therapy related acute promyelocytic leukemia with the combination of alltransretinoic acid and arsenic trioxide without chemotherapy: a series of three patients. Leukemia and Lymphoma, 2010, 51, 933-936.	0.6	11
146	Childhood Medulloblastoma. CNS Drugs, 2010, 24, 285-301.	2.7	26
147	Arsenic trioxide cooperates with alltransretinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PMLâ€“RARÎ± negative human myeloblastic leukemia cells. Leukemia and Lymphoma, 2010, 51, 1-14.	0.6	43
148	Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Expert Opinion on Biological Therapy, 2011, 11, 225-234.	1.4	34
149	Le urgenze ematologiche. Italian Journal of Medicine, 2011, 5, 238-248.	0.2	0
150	A Case of Acute Promyelocytic Leukemia Without RARÎ± Rearrangement and Apparently Normal Cytogenetics. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 521-524.	0.2	0
151	An Evidence-based Perspective of Arsenic Trioxide (As2O3) for Cancer Patients. Evidence-based Anticancer Complementary and Alternative Medicine, 2011, , 37-64.	0.1	1
152	Epigenetic Mechanisms in Acute Myeloid Leukemia. , 2011, 67, 197-219.		8
153	Epigenetics and Disease. , 2011, , .		5
154	Cellular Effects of Heavy Metals. , 2011, , .		60
155	Increased expression of protease-activated receptor 1 (PAR-1) in human leukemias. Blood Cells, Molecules, and Diseases, 2011, 46, 230-234.	0.6	17

#	Article	IF	Citations
156	Lead acetate and arsenic trioxide induce instability of microsatellites at three different fragile sites (6q21, 9q32â€“9q33 and 15p14) within the genome of the rat. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2011, 726, 195-199.	0.9	9
157	Carotenoids and Alzheimerâ€™s Disease: An insight into therapeutic role of retinoids in animal models. Neurochemistry International, 2011, 59, 535-541.	1.9	104
158	ManifestaciÃ³n de leucemia promielocÃtica aguda en el embarazo. Progresos En Obstetricia Y Ginecologia, 2011, 54, 428-430.	0.0	2
159	The Drug-Induced Degradation of Oncoproteins: An Unexpected Achilles' Heel of Cancer Cells?. Cancer Discovery, 2011, 1, 117-127.	7.7	45
160	E-box-independent regulation of transcription and differentiation by MYC. Nature Cell Biology, 2011, 13, 1443-1449.	4.6	37
161	Treatment outcome of all-transretinoic acid/anthracycline combination chemotherapy and the prognostic impact ofFLT3/ITD mutation in acute promyelocytic leukemia patients. The Korean Journal of Hematology, 2011, 46, 24.	0.7	21
163	Immunophenotyping of the Blast Cells in Correlations with the Molecular Genetics Analyses for Diagnostic and Clinical Stratification of Patients with Acute Myeloid Leukemia: Single Center Experience. , 0, , .		0
164	Arsenic Exposure and the Induction of Human Cancers. Journal of Toxicology, 2011, 2011, 1-13.	1.4	322
165	The Role of Genetics. Oncology Issues, 2011, 26, 38-43.	0.0	0
166	ED in APL: tip of the iceberg?. Blood, 2011, 118, 1188-1189.	0.6	7
167	From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood, 2011, 117, 6425-6437.	0.6	170
168	Do reactive oxygen species play a role in myeloid leukemias?. Blood, 2011, 117, 5816-5826.	0.6	201
169	Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood, 2011, 118, 1600-1609.	0.6	105
170	Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood, 2011, 117, 5795-5802.	0.6	111
171	Acute leukemia in adults. Hematologie, 2011, 17, 203-224.	0.0	1
172	HLA-DRnegative, CD34negative Hypergranular Acute Myeloid Leukemia With Trisomy 6 and del(5)(q22q33). Journal of Pediatric Hematology/Oncology, 2011, 33, e289-e295.	0.3	2
173	Advances in therapies for acute promyelocytic leukemia. Cancer Science, 2011, 102, 1929-1937.	1.7	39
174	Melatonin promotes puromycinâ€induced apoptosis with activation of caspaseâ€3 and 5â€²â€adenosine monophosphateâ€activated kinaseâ€alpha in human leukemia HLâ€60 cells. Journal of Pineal Research, 2011, 50, 367-373.	3.4	37

#	Article	IF	Citations
175	TRIM proteins and cancer. Nature Reviews Cancer, 2011, 11, 792-804.	12.8	641
176	Raf kinases in cancerâ€“roles and therapeutic opportunities. Oncogene, 2011, 30, 3477-3488.	2.6	247
177	Ras and Raf pathways in epidermis development and carcinogenesis. British Journal of Cancer, 2011, 104, 229-234.	2.9	57
178	Genome-wide functions of PMLâ€“RARÎ± in acute promyelocytic leukaemia. British Journal of Cancer, 2011, 104, 554-558.	2.9	54
179	Gene expression profiling in MDS and AML: potential and future avenues. Leukemia, 2011, 25, 909-920.	3.3	64
180	Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia, 2011, 25, 1128-1134.	3.3	276
182	FLT3 internal tandem duplication is associated with a high relapse rate and central nervous system involvement in acute promyelocytic leukemia cases: single institutional analysis. European Journal of Haematology, 2011, 86, 272-273.	1.1	10
183	Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes. Toxicology and Applied Pharmacology, 2011, 257, 198-208.	1.3	40
184	The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: A meta-analysis. Leukemia Research, 2011, 35, 1170-1177.	0.4	27
185	Transcriptional and epigenetic networks in haematological malignancy. FEBS Letters, 2011, 585, 2100-2111.	1.3	32
186	An in vivo analysis of the therapeutic and synergistic properties of Chinese medicinal formula Yin-Chen-Hao-Tang based on its active constituents. FÃ¬toterapÃ¬Ã¢, 2011, 82, 1160-1168.	1.1	104
187	Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation. Biochemical Pharmacology, 2011, 82, 1619-1629.	2.0	49
188	Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: Requirement for Cyp1a1. Chemico-Biological Interactions, 2011, 193, 88-96.	1.7	4
189	Promyelocytic leukemia nuclear bodies support a late step in DNA doubleâ€strand break repair by homologous recombination. Journal of Cellular Biochemistry, 2012, 113, 1787-1799.	1.2	33
190	ATRA and anthracycline-based chemotherapy in the treatment of childhood acute promyelocytic leukemia (APL): A 10-year experience in Tunisia. Medical Oncology, 2011, 28, 1618-1623.	1.2	9
191	Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients. Medical Oncology, 2011, 28, 513-521.	1.2	23
192	Combined Inhibition of PI3K and mTOR Exerts Synergistic Antiproliferative Effect, but Diminishes Differentiative Properties of Rapamycin in Acute Myeloid Leukemia Cells. Pathology and Oncology Research, 2011, 17, 645-656.	0.9	14
193	Synthesis of C 6-epimer derivatives of diacetoxy acetal derivative of santonin and their inducing effects on HL-60 leukemia cell differentiation. Archives of Pharmacal Research, 2011, 34, 191-198.	2.7	3

#	Article	IF	Citations
194	Therapy-related T-cell lymphoblastic lymphoma and inv(11)(q21q23) following acute promyelocytic leukemia chemotherapy. Journal of Hematopathology, 2011, 4, 127-131.	0.2	0
195	Translational medicine: What is in a name from the perspective of Chinese clinicians?. Science China Life Sciences, 2011, 54, 1077-1080.	2.3	6
196	Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction. Frontiers of Medicine, 2011, 5, 45-52.	1.5	3
197	Traditional Chinese medicine in the new century. Frontiers of Medicine, 2011, 5, 111-114.	1.5	8
198	Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells. Molecular Cancer, 2011, 10, 142.	7.9	101
199	Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells. Journal of Translational Medicine, 2011, 9, 74.	1.8	23
200	Redox platforms in cancer drug discovery and development. Current Opinion in Chemical Biology, 2011, 15, 156-161.	2.8	46
201	Shooting the messenger: Targeting signal transduction pathways in leukemia and related disorders. Critical Reviews in Oncology/Hematology, 2011, 78, 33-44.	2.0	8
202	Untangling the intracellular signalling network in cancer â€" A strategy for data integration in acute myeloid leukaemia. Journal of Proteomics, 2011, 74, 269-281.	1.2	6
203	Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. Leukemia Research, 2011, 35, 152-158.	0.4	40
204	KLFs and ATRA-induced differentiation: New pathways for exploitation. Leukemia Research, 2011, 35, 846-847.	0.4	8
205	Advances in metal-induced oxidative stress and human disease. Toxicology, 2011, 283, 65-87.	2.0	2,397
206	Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells. Cell Biology International, 2011, 35, 803-810.	1.4	21
207	Exploring Old Drugs for the Treatment of Hematological Malignancies. Current Medicinal Chemistry, 2011, 18, 1509-1514.	1.2	9
208	Retinoic Acid as a Vaccine Adjuvant Enhances CD8⁺T Cell Response and Mucosal Protection from Viral Challenge. Journal of Virology, 2011, 85, 8316-8327.	1.5	82
209	Effector Caspases and Leukemia. International Journal of Cell Biology, 2011, 2011, 1-8.	1.0	20
211	Oxidative Inactivation of the Lipid Phosphatase Phosphatase and Tensin Homolog on Chromosome Ten (PTEN) as a Novel Mechanism of Acquired Long QT Syndrome*. Journal of Biological Chemistry, 2011, 286, 2843-2852.	1.6	23
212	MUC1-C oncoprotein suppresses reactive oxygen speciesâ€"induced terminal differentiation of acute myelogenous leukemia cells. Blood, 2011, 117, 4863-4870.	0.6	33

#	Article	IF	Citations
213	Multiple cytochromeP-450 genes are concomitantly regulated by vitamin A under steady-state conditions and by retinoic acid during hepatic first-pass metabolism. Physiological Genomics, 2011, 43, 57-67.	1.0	32
214	Differentiation Therapy of Acute Myeloid Leukemia. Cancers, 2011, 3, 2402-2420.	1.7	37
215	ACUTE PROMYELOCYTIC LEUKEMIA: AN EXPERIENCE ON 95 GREEK PATIENTS TREATED IN THE ALL-TRANS-RETINOIC ACID ERA. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011053.	0.5	13
216	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH SINGLE-AGENT ARSENIC TRIOXIDE. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011056.	0.5	39
217	EXTRAMEDULLARY DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA: TWO-IN-ONE DISEASE. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011066.	0.5	16
218	HISTORY OF ACUTE PROMYELOCYTIC LEUKEMIA: A TALE OF ENDLESS REVOLUTION. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011067.	0.5	27
219	DIFFERENTIATION SYNDROME IN PROMYELOCYTIC LEUKEMIA : CLINICAL PRESENTATION, PATHOGENESIS AND TREATMENT. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011048.	0.5	30
220	Synergistic Apoptosis-Inducing Antileukemic Effects of Arsenic Trioxide andMucuna macrocarpaStem Extract in Human Leukemic Cells via a Reactive Oxygen Species-Dependent Mechanism. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-14.	0.5	10
221	Carbonyl Reductase 1 Offers a Novel Therapeutic Target to Enhance Leukemia Treatment by Arsenic Trioxide. Cancer Research, 2012, 72, 4214-4224.	0.4	24
222	Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood, 2012, 119, 49-54.	0.6	63
223	Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies. Current Molecular Medicine, 2012, 12, 746-762.	0.6	6
224	Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor. Acta Pharmacologica Sinica, 2012, 33, 212-213.	2.8	2
225	Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia, 2012, 26, 1630-1637.	3.3	48
226	Novel strategies in treatment of acute promyelocytic leukemia. Leukemia Supplements, 2012, 1, S18-S19.	0.1	0
227	Cure Models as a Useful Statistical Tool for Analyzing Survival. Clinical Cancer Research, 2012, 18, 3731-3736.	3.2	160
228	Pathogenesis and treatment of leukemia: an Asian perspective. Expert Opinion on Therapeutic Targets, 2012, 16, S37-S43.	1.5	9
229	Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cells. International Journal of Oncology, 2012, 40, 1089-1096.	1.4	24
230	Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia. Hematology, 2012, 17, 311-316.	0.7	13

#	Article	IF	Citations
231	Who Benefits From Maintenance Therapy in Acute Promyelocytic Leukemia?. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1023-1028.	2.3	1
233	Interferon-Î³ enhances promyelocytic leukemia protein expression in acute promyelocytic cells and cooperates with all-trans-retinoic acid to induce maturation of NB4 and NB4-R1 cells. Experimental and Therapeutic Medicine, 2012, 3, 776-780.	0.8	10
234	Cytogenetics of acute leukemias. , 0, , 135-167.		1
235	Molecular genetics of acute myeloid leukemia. , 0, , 204-238.		2
236	Minimal residual disease. , 0, , 632-659.		0
237	Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica, 2012, 97, 133-136.	1.7	122
238	Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica, 2012, 97, 227-234.	1.7	57
239	Establishment of two-dimensional gel electrophoresis profiles of the human acute promyelocytic leukemia cell line NB4. Molecular Medicine Reports, 2012, 6, 570-574.	1.1	4
240	Lentiviral vector-mediated RNA interference targeted against prohibitin inhibits apoptosis of the retinoic acid-resistant acute promyelocytic leukemia cell line NB4-R1. Molecular Medicine Reports, 2012, 6, 1288-1292.	1.1	9
242	Phagocytosis by macrophages and endothelial cells inhibits procoagulant and fibrinolytic activity of acute promyelocytic leukemia cells. Blood, 2012, 119, 2325-2334.	0.6	41
243	Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. Blood, 2012, 119, 3413-3419.	0.6	45
244	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 2012, 120, 1570-1580.	0.6	268
245	A Meg by any other name. Blood, 2012, 120, 1970-1971.	0.6	0
246	Mutation associations in RA-defiant APL. Blood, 2012, 120, 1969-1970.	0.6	1
247	Acute promyelocytic leukemia, arsenic, and PML bodies. Journal of Cell Biology, 2012, 198, 11-21.	2.3	177
248	Cblâ€bâ€dependent degradation of FLIP_L is involved in ATOâ€induced autophagy in leukemic K562 and gastric cancer cells. FEBS Letters, 2012, 586, 3104-3110.	1.3	17
249	Arsenic-induced inhibition of hippocampal neurogenesis and its reversibility. NeuroToxicology, 2012, 33, 1033-1039.	1.4	41
250	Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Review of Molecular Diagnostics, 2012, 12, 593-602.	1.5	87

#	Article	IF	Citations
251	Targeted therapy in rare cancersâ€"adopting the orphans. Nature Reviews Clinical Oncology, 2012, 9, 631-642.	12.5	39
252	Targeting of AML1-ETO in t(8;21) Leukemia by Oridonin Generates a Tumor Suppressorâ€"Like Protein. Science Translational Medicine, 2012, 4, 127ra38.	5.8	76
253	Curing APL through PML/RARA degradation by As2O3. Trends in Molecular Medicine, 2012, 18, 36-42.	3.5	126
254	Regulatory role of KEAP1 and NRF2 in PPARÎ³ expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radical Biology and Medicine, 2012, 53, 758-768.	1.3	53
255	Differentiation syndrome in patients with acute promyelocytic leukemia. Journal of Oncology Pharmacy Practice, 2012, 18, 109-114.	0.5	47
256	Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression. Journal of Cellular Biochemistry, 2012, 113, 3528-3535.	1.2	44
257	The role of PML ubiquitination in human malignancies. Journal of Biomedical Science, 2012, 19, 81.	2.6	27
258	The significance of low PU.1 expression in patients with acute promyelocytic leukemia. Journal of Hematology and Oncology, 2012, 5, 22.	6.9	20
259	Evidence-based Anticancer Materia Medica for Leukemia. Evidence-based Anticancer Complementary and Alternative Medicine, 2012, , 229-259.	0.1	0
260	Causes for refusal or abandonment during treatment of pediatric acute promyelocytic leukemia. Leukemia Research, 2012, 36, e193-e194.	0.4	14
261	Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia, 2012, 26, 563-571.	3.3	56
262	Cytocidal Effects of Polyphenolic Compounds, Alone or in Combination with, Anticancer Drugs Against Cancer Cells: Potential Future Application of the Combinatory Therapy. , 2012, , .		5
263	The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience. Medical Oncology, 2012, 29, 2088-2094.	1.2	7
264	Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opinion on Pharmacotherapy, 2012, 13, 1031-1043.	0.9	46
265	(+)Î±-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. Leukemia, 2012, 26, 451-460.	3.3	60
266	Arsenic Trioxide Exerts Antimyeloma Effects by Inhibiting Activity in the Cytoplasmic Substrates of Histone Deacetylase 6. PLoS ONE, 2012, 7, e32215.	1.1	22
267	Near Infrared Imaging of EGFR of Oral Squamous Cell Carcinoma in Mice Administered Arsenic Trioxide. PLoS ONE, 2012, 7, e46255.	1.1	8
268	Matrine Induces Apoptosis in Human Acute Myeloid Leukemia Cells via the Mitochondrial Pathway and Akt Inactivation. PLoS ONE, 2012, 7, e46853.	1.1	105

#	Article	IF	Citations
269	Study Designs and Statistical Analyses for Biomarker Research. Sensors, 2012, 12, 8966-8986.	2.1	67
270	History of leukemia: historical perspectives. , 0, , 1-20.		3
271	Comprehensive FLT3 analysis in Indian acute myeloid leukaemia. Journal of Blood & Lymph, 2012, 02, .	0.0	2
272	Retinoids in the treatment of glioma: a new perspective. Cancer Management and Research, 2012, 4, 233.	0.9	21
273	Hematologic emergencies. Italian Journal of Medicine, 2012, , 238-248.	0.2	0
274	ZBTB16-RARÎ±variant of acute promyelocytic leukemia with tuberculosis: a case report and review of literature. The Korean Journal of Hematology, 2012, 47, 229.	0.7	4
275	Retinoic acid and cAMP inhibit rat hepatocellular carcinoma cell proliferation and enhance cell differentiation. Brazilian Journal of Medical and Biological Research, 2012, 45, 721-729.	0.7	17
276	Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. Journal of Hematology and Oncology, 2012, 5, 1.	6.9	85
277	Identification of Drugs IncludingÂa DopamineÂReceptor Antagonist that Selectively Target Cancer Stem Cells. Cell, 2012, 149, 1284-1297.	13.5	420
278	Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nature Chemical Biology, 2012, 8, 486-493.	3.9	176
279	SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3. Genes Chromosomes and Cancer, 2012, 51, 756-767.	1.5	16
280	Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond. IUBMB Life, 2012, 64, 671-675.	1.5	10
281	Simultaneous in vivo RPâ€HPLCâ€DAD quantification of multipleâ€component and drugâ€“drug interaction by pharmacokinetics, using 6,7â€dimethylesculetin, geniposide and rhein as examples. Biomedical Chromatography, 2012, 26, 844-850.	0.8	46
282	Arsenic compounds: revived ancient remedies in the fight against human malignancies. Current Opinion in Chemical Biology, 2012, 16, 92-98.	2.8	66
283	Single-Nucleotide Polymorphism Array Karyotyping in Clinical Practice: Where, When, and How?. Seminars in Oncology, 2012, 39, 13-25.	0.8	33
284	Regulation of the hematopoietic cell kinase (HCK) by PML/RARÎ± and PU.1 in acute promyelocytic leukemia. Leukemia Research, 2012, 36, 219-223.	0.4	10
285	SUMO playing tag with ubiquitin. Trends in Biochemical Sciences, 2012, 37, 23-31.	3.7	139
286	Methanol extract of Antrodia cinnamomea mycelia induces phenotypic and functional differentiation of HL60 into monocyte-like cells via an ERK/CEBP-Î² signaling pathway. Phytomedicine, 2012, 19, 424-435.	2.3	12

#	Article	IF	Citations
287	How to write research papers and grants: 2011 Asian Pacific Society for Respirology Annual Scientific Meeting Postgraduate Session. Respirology, 2012, 17, 792-801.	1.3	3
288	Survival and cure of acute myeloid leukaemia in <scp>E</scp>ngland, 1971â€“2006: a populationâ€“based study. British Journal of Haematology, 2013, 162, 509-516.	1.2	177
289	Dr. Zhen-Yi Wang: Fighting leukemia. Protein and Cell, 2013, 4, 483-484.	4.8	0
290	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. New England Journal of Medicine, 2013, 369, 111-121.	13.9	1,284
291	Role of Arsenic Trioxide in Acute Promyelocytic Leukemia. Current Treatment Options in Oncology, 2013, 14, 170-184.	1.3	40
292	Management of elderly patients with acute promyelocytic leukemia: progress and problems. Annals of Hematology, 2013, 92, 1181-1188.	0.8	30
293	Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest. Annals of Hematology, 2013, 92, 1207-1220.	0.8	22
294	A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. Science China Life Sciences, 2013, 56, 495-502.	2.3	48
296	Mesenchymal Stem Cells Induce Granulocytic Differentiation of Acute Promyelocytic Leukemic Cells via IL-6 and MEK/ERK Pathways. Stem Cells and Development, 2013, 22, 1955-1967.	1.1	15
297	Targeting Agents Alone to Cure Acute Promyelocytic Leukemia. New England Journal of Medicine, 2013, 369, 186-187.	13.9	19
298	Time-Lapse AFM Imaging of DNA Conformational Changes Induced by Daunorubicin. Nano Letters, 2013, 13, 5679-5684.	4.5	27
299	Anticancer Activity of Small-Molecule and Nanoparticulate Arsenic(III) Complexes. Inorganic Chemistry, 2013, 52, 12292-12304.	1.9	81
300	Acute promyelocytic leukemia; early diagnosis is the key to survival. American Journal of Emergency Medicine, 2013, 31, 1290.e1-1290.e2.	0.7	6
301	Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical Epigenetics, 2013, 5, 12.	1.8	79
302	Arsenic trioxide prevents nitric oxide production in lipopolysaccharide â€stimulated <scp>RAW</scp> 264.7 by inhibiting a <scp>TRIF</scp>â€dependent pathway. Cancer Science, 2013, 104, 165-170.	1.7	26
303	A single course of allâ€trans retinoic acid plus arsenic trioxide reached a longâ€term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?. European Journal of Haematology, 2013, 91, 470-471.	1.1	17
304	Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions. Expert Review of Anticancer Therapy, 2013, 13, 1035-1043.	1.1	11
305	A New Chromosome Translocation t(7;16)(q31,q22) Change during an Acute Promyelocytic Leukemia Relapse. Cytogenetic and Genome Research, 2013, 141, 70-74.	0.6	0

#	Article	IF	Citations
306	Rapid detection of PMLâ€“RARA fusion gene by novel high-speed droplet-reverse transcriptase-polymerase chain reaction: Possibility for molecular diagnosis without lagging behind the morphological analyses. Clinica Chimica Acta, 2013, 415, 276-278.	0.5	11
307	Targeting peroxiredoxins against leukemia. Experimental Cell Research, 2013, 319, 170-176.	1.2	26
308	Chloroquine enhances cobalt chloride-induced leukemic cell differentiation via the suppression of autophagy at the late phase. Biochemical and Biophysical Research Communications, 2013, 430, 926-932.	1.0	13
309	How animal models of leukaemias have already benefited patients. Molecular Oncology, 2013, 7, 224-231.	2.1	8
311	Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leukemia Research, 2013, 37, 1004-1009.	0.4	98
312	Dual roles for lysine 490 of promyelocytic leukemia protein in the transactivation of glucocorticoid receptor-interacting protein 1. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1799-1810.	1.9	6
313	A novel acidic serine protease, ASPNJ inhibits proliferation, induces apoptosis and enhances chemo-susceptibility of acute promyelocytic leukemia cell. Leukemia Research, 2013, 37, 1697-1703.	0.4	7
314	The Histone Demethylase PHF8 Governs Retinoic Acid Response in Acute Promyelocytic Leukemia. Cancer Cell, 2013, 23, 376-389.	7.7	76
315	Synergistic effect of retinoic acid and vitamin D analog EB1089-induced apoptosis of hepatocellular cancer cells. Cytotechnology, 2013, 65, 457-465.	0.7	6
316	Decoding the SUMO signal. Biochemical Society Transactions, 2013, 41, 463-473.	1.6	105
317	Interplay between the Cancer Genome and Epigenome. Cell, 2013, 153, 38-55.	13.5	733
318	PML Degradation: Multiple Ways to Eliminate PML. Frontiers in Oncology, 2013, 3, 60.	1.3	17
319	Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation. Science, 2013, 340, 622-626.	6.0	721
320	The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability. Oncogene, 2013, 32, 5167-5175.	2.6	31
321	Liquid Bead Array Technology in the Detection of Common Translocations in Acute and Chronic Leukemias. Methods in Molecular Biology, 2013, 999, 93-103.	0.4	3
322	Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia. International Journal of Hematology, 2013, 97, 717-725.	0.7	151
323	p101. , 2013, , 1623-1623.		0
324	Micro<scp>RNA</scp>s in myeloid malignancies. British Journal of Haematology, 2013, 162, 162-176.	1.2	39

#	Article	IF	Citations
325	High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leukemia Research, 2013, 37, 37-42.	0.4	26
326	Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide. Leukemia and Lymphoma, 2013, 54, 2041-2046.	0.6	7
327	Differentiation therapy for IDH1/2 mutant malignancies. Cell Research, 2013, 23, 975-977.	5.7	8
328	Clinical characteristics of acute promyelocytic leukemia manifesting as early death. Molecular and Clinical Oncology, 2013, 1, 908-910.	0.4	9
329	Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. Journal of Experimental Medicine, 2013, 210, 2793-2802.	4.2	121
330	Rare Occurrence of the JAK1 Mutation in Acute Promyelocytic Leukemia Patients. Acta Haematologica, 2013, 130, 251-253.	0.7	1
331	Arsenic Trioxide Inhibits the Hedgehog Pathway Which Is Aberrantly Activated in Acute Promyelocytic Leukemia. Acta Haematologica, 2013, 130, 260-267.	0.7	29
332	MicroRNAs Contribute to Promyelocyte Apoptosis in As₂O₃-Treated APL Cells. Cellular Physiology and Biochemistry, 2013, 32, 1818-1829.	1.1	31
333	Acute Promyelocytic Leukemia with Flt3-TKD and WT1 Mutations Relapsing in a Testicle and Followed by Systemic Relapse. Acta Haematologica, 2013, 130, 223-229.	0.7	5
334	Arkadia, a Novel SUMO-Targeted Ubiquitin Ligase Involved in PML Degradation. Molecular and Cellular Biology, 2013, 33, 2163-2177.	1.1	81
335	Metabolomics Coupled with Proteomics Advancing Drug Discovery toward More Agile Development of Targeted Combination Therapies. Molecular and Cellular Proteomics, 2013, 12, 1226-1238.	2.5	142
336	Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells. Cell Death and Disease, 2013, 4, e633-e633.	2.7	54
337	8-CPT-cAMP/all- trans retinoic acid targets t (11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARÎ± degradation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3495-3500.	3.3	16
340	Oleanolic acid inhibits proliferation and induces apoptosis in NB4 cells by targeting PML/RARÎ±. Oncology Letters, 2013, 6, 885-890.	0.8	14
341	Hepatotoxicity From Arsenic Trioxide for Pediatric Acute Promyelocytic Leukemia. Journal of Pediatric Hematology/Oncology, 2013, Publish Ahead of Print, e67-70.	0.3	13
342	Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts. Oncology Reports, 2013, 29, 2362-2368.	1.2	22
343	Involvement of histone H3 phosphorylation through p38 MAPK pathway activation in casticin-induced cytocidal effects against the human promyelocytic cell line HL-60. International Journal of Oncology, 2013, 43, 2046-2056.	1.4	36
344	Comparison of laboratory characteristics between acute promyelocytic leukemia and other subtypes of acute myeloid leukemia with disseminated intravascular coagulation. Blood Research, 2013, 48, 250.	0.5	25

#	Article	IF	Citations
345	Silencing of the human SET gene in vitro with lentivirus-mediated RNA interference. Molecular Medicine Reports, 2013, 7, 843-847.	1.1	2
346	MEK/ERK Dependent Activation of STAT1 Mediates Dasatinib-Induced Differentiation of Acute Myeloid Leukemia. PLoS ONE, 2013, 8, e66915.	1.1	35
347	Molecular oncology of acute promyelocytic leukemia (APL). , 0, , 769-776.		0
348	Megakaryocytic Differentiation of K562 Cells Induced by PMA Reduced the Activity of Respiratory Chain Complex IV. PLoS ONE, 2014, 9, e96246.	1.1	39
349	Arsenic Sulfide Promotes Apoptosis in Retinoid Acid Resistant Human Acute Promyelocytic Leukemic NB4-R1 Cells through Downregulation of SET Protein. PLoS ONE, 2014, 9, e83184.	1.1	5
350	Matrix Metalloproteinase-9 Is Involved in Chronic Lymphocytic Leukemia Cell Response to Fludarabine and Arsenic Trioxide. PLoS ONE, 2014, 9, e99993.	1.1	10
351	ATO/ATRA/Anthracycline-Chemotherapy Sequential Consolidation Achieves Long-Term Efficacy in Primary Acute Promyelocytic Leukemia. PLoS ONE, 2014, 9, e104610.	1.1	13
352	Targeting Catalase but Not Peroxiredoxins Enhances Arsenic Trioxide-Induced Apoptosis in K562 Cells. PLoS ONE, 2014, 9, e104985.	1.1	15
353	NSFC Health Research Funding and Burden of Disease in China. PLoS ONE, 2014, 9, e111458.	1.1	23
354	Induced Differentiation of Human Myeloid Leukemia Cells into M2 Macrophages by Combined Treatment with Retinoic Acid and 1Î±,25-Dihydroxyvitamin D3. PLoS ONE, 2014, 9, e113722.	1.1	30
355	L-asparaginase induces in AML U937 cells apoptosis via an AIF-mediated mechanism. Frontiers in Bioscience - Landmark, 2014, 19, 515.	3.0	12
356	Data Analytics for Traditional Chinese Medicine Research. , 2014, , .		9
357	Involvement of oxidative stress associated with glutathione depletion and p38 mitogen-activated protein kinase activation in arsenic disulfide-induced differentiation in HL-60 cells. Leukemia and Lymphoma, 2014, 55, 392-404.	0.6	23
358	A HIF-1 network reveals characteristics of epithelial-mesenchymal transition in acute promyelocytic leukemia. Genome Medicine, 2014, 6, 84.	3.6	18
359	Transcriptional repression of CDKN2D by PML/RARÎ± contributes to the altered proliferation and differentiation block of acute promyelocytic leukemia cells. Cell Death and Disease, 2014, 5, e1431-e1431.	2.7	34
360	Perspectives of Differentiation Therapies of Acute Myeloid Leukemia: The Search for the Molecular Basis of PatientsÃ¢â‚¬â„¢ Variable Responses to 1,25-Dihydroxyvitamin D and Vitamin D Analogs. Frontiers in Oncology, 2014, 4, 125.	1.3	35
362	Rapid Reduction in Breast Cancer Mortality With Inorganic Arsenic in Drinking Water. EBioMedicine, 2014, 1, 58-63.	2.7	28
363	ERK5 Pathway Regulates Transcription Factors Important for Monocytic Differentiation of Human Myeloid Leukemia Cells. Journal of Cellular Physiology, 2014, 229, 856-867.	2.0	25

#	Article	IF	Citations
364	Enhancement of Allâ€Trans Retinoic Acidâ€Induced Differentiation by pHâ€Sensitive Nanoparticles for Solid Tumor Cells. Macromolecular Bioscience, 2014, 14, 369-379.	2.1	18
365	Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. European Journal of Haematology, 2014, 93, 54-62.	1.1	11
366	BIMELis a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine. BMC Cancer, 2014, 14, 27.	1.1	15
367	Catechins induced acute promyelocytic leukemia cell apoptosis and triggered PML-RARÎ± oncoprotein degradation. Journal of Hematology and Oncology, 2014, 7, 75.	6.9	21
368	ATRA + ATO. Current Opinion in Hematology, 2014, 21, 95-101.	1.2	7
369	Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia. Hematology, 2014, 19, 202-207.	0.7	9
370	Tamibarotene for the treatment of acute promyelocytic leukemia. Expert Opinion on Orphan Drugs, 2014, 2, 961-969.	0.5	1
371	Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: Case report. Journal of International Medical Research, 2014, 42, 1363-1373.	0.4	2
372	Regulatory Effects of Arsenic on Cellular Signaling Pathways: Biological Effects and Therapeutic Implications. Cancer Drug Discovery and Development, 2014, , 107-119.	0.2	2
373	Biomarkers in pharmacology and drug discovery. Biochemical Pharmacology, 2014, 87, 172-188.	2.0	56
374	Safflower yellow for acute ischemic stroke: A systematic review of randomized controlled trials. Complementary Therapies in Medicine, 2014, 22, 354-361.	1.3	35
375	Severe Aplastic Anemia Manifesting After Complete Remission of Acute Promyelocytic Leukemia: Is it a Fortuitous Association?. Indian Journal of Hematology and Blood Transfusion, 2014, 30, 64-67.	0.3	1
376	Preparation and investigation of arsenic trioxide-loaded polylactic acid/magnetic hybrid nanoparticles. Chemical Research in Chinese Universities, 2014, 30, 326-332.	1.3	18
377	Tetra-arsenic tetra-sulfide (As4S4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein. Tumor Biology, 2014, 35, 3421-3430.	0.8	7
378	Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy. Annals of Hematology, 2014, 93, 941-948.	0.8	14
379	Oxidative stress induced by the chemotherapeutic agent arsenic trioxide. 3 Biotech, 2014, 4, 425-430.	1.1	10
380	Topoisomerase II and leukemia. Annals of the New York Academy of Sciences, 2014, 1310, 98-110.	1.8	163
381	Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7. Chinese Journal of Integrative Medicine, 2014, 20, 387-393.	0.7	13

#	Article	IF	Citations
382	The coagulopathy in acute promyelocytic leukaemia â€“ What have we learned in the past twenty years. Best Practice and Research in Clinical Haematology, 2014, 27, 11-18.	0.7	50
383	Monocytic differentiation induced by side-chain modified analogs of vitamin D in ex vivo cells from patients with acute myeloid leukemia. Leukemia Research, 2014, 38, 638-647.	0.4	23
384	Molecular Testing in Cancer. , 2014, , .		2
385	Binding affinity and efficacy-based pharmacophore modeling studies of retinoic acid receptor alpha agonists and virtual screening for potential agonists from NCI. Medicinal Chemistry Research, 2014, 23, 3916-3926.	1.1	3
386	NPMâ€“RAR, not the RARâ€“NPM reciprocal t(5;17)(q35;q21) acute promyelocytic leukemia fusion protein, inhibits myeloid differentiation. Leukemia and Lymphoma, 2014, 55, 1383-1387.	0.6	9
388	Erythroid and megakaryocytic differentiation of K562 erythroleukemic cells by monochloramine. Free Radical Research, 2014, 48, 292-302.	1.5	8
389	Regulation of Death Induction and Chemosensitizing Action of 3-Bromopyruvate in Myeloid Leukemia Cells: Energy Depletion, Oxidative Stress, and Protein Kinase Activity Modulation. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 324-335.	1.3	32
390	Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood, 2014, 123, 1341-1352.	0.6	107
391	Cancer research in France. International Journal of Cancer, 2014, 135, 2235-2236.	2.3	0
392	Quantitative implementation of the endogenous molecularâ€“cellular network hypothesis in hepatocellular carcinoma. Interface Focus, 2014, 4, 20130064.	1.5	26
393	Cost of Treating Acute Promyelocytic Leukemia (APL) Patients in Italy. Value in Health, 2014, 17, A624.	0.1	0
394	ZRF1 controls the retinoic acid pathway and regulates leukemogenic potential in acute myeloid leukemia. Oncogene, 2014, 33, 5501-5510.	2.6	22
395	Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes. Journal of Clinical Oncology, 2014, 32, 3406-3412.	0.8	76
396	miR-203, a Tumor Suppressor Frequently Down-regulated by Promoter Hypermethylation in Rhabdomyosarcoma. Journal of Biological Chemistry, 2014, 289, 529-539.	1.6	75
397	Combining nanodiamond and all trans retinoic acid to increase the apoptosis of HL-60 cell. Materials Letters, 2014, 133, 262-265.	1.3	8
398	Silica nanovehicles endow arsenic trioxide with an ability to effectively treat cancer cells and solid tumors. Journal of Materials Chemistry B, 2014, 2, 6313.	2.9	29
399	Mechanistic aspects of lauryl gallate-induced differentiation and apoptosis in human acute myeloid leukemia cells. Food and Chemical Toxicology, 2014, 71, 197-206.	1.8	10
400	New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach. Clinical Cancer Research, 2014, 20, 4985-4993.	3.2	14

#	Article	IF	Citations
401	C/EBPÎ±: critical at the origin of leukemic transformation. Journal of Experimental Medicine, 2014, 211, 1-4.	4.2	27
402	Retinoid receptor signaling and autophagy in acute promyelocytic leukemia. Experimental Cell Research, 2014, 324, 1-12.	1.2	37
403	Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. British Journal of Haematology, 2014, 165, 497-503.	1.2	38
404	What is the Standard Regimen for Patients with Acute Promyelocytic Leukemia?. Current Hematologic Malignancy Reports, 2014, 9, 138-143.	1.2	10
405	Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction. International Journal of Hematology, 2014, 100, 38-50.	0.7	17
406	Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. Cellular Oncology (Dordrecht), 2014, 37, 119-129.	2.1	52
407	Arsenic trioxide inhibits transforming growth factor-Î²1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. Respiratory Research, 2014, 15, 51.	1.4	46
408	Retiferols â€“ synthesis and biological activity of a conceptually novel class of vitamin D analogs. Expert Opinion on Therapeutic Patents, 2014, 24, 633-646.	2.4	6
409	Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. European Journal of Cancer, 2014, 50, 1159-1168.	1.3	24
410	Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thrombosis Research, 2014, 133, 303-305.	0.8	28
411	Advanced progress on the relationship between RA and its receptors and malignant tumors. Critical Reviews in Oncology/Hematology, 2014, 91, 271-282.	2.0	14
412	Development of yeast reporter assay for screening specific ligands of retinoic acid and retinoid X receptor subtypes. Journal of Pharmacological and Toxicological Methods, 2014, 69, 245-252.	0.3	18
413	Triple A therapy: The molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide. Best Practice and Research in Clinical Haematology, 2014, 27, 19-31.	0.7	11
414	IKKÎ± restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. Nature Communications, 2014, 5, 3661.	5.8	67
415	Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. Thrombosis Research, 2014, 133, S112-S116.	0.8	41
416	An ider(17)(q10)t(15;17) with spliced long-type PML-RARA fusion transcripts in a case of acute promyelocytic leukemia. Cancer Genetics, 2014, 207, 253-257.	0.2	4
417	Coordinated regulation of the immunoproteasome subunits by PML/RARÎ± and PU.1 in acute promyelocytic leukemia. Oncogene, 2014, 33, 2700-2708.	2.6	27
418	Thyroid tumor-initiating cells: Increasing evidence and opportunities for anticancer therapy (Review). Oncology Reports, 2014, 31, 1035-1042.	1.2	23

#	Article	IF	Citations
419	TBLR1 fuses to retinoid acid receptor Î± in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia. Blood, 2014, 124, 936-945.	0.6	51
420	Enhancement of differentiation induction and upregulation of CCAAT/enhancer-binding proteins and PU.1 in NB4 cells treated with combination of ATRA and valproic acid. International Journal of Oncology, 2014, 44, 865-873.	1.4	20
422	Therapy-induced Secondary Acute Myeloid Leukemia With t(11;19)(q23;p13.1) in a Pediatric Patient With Relapsed Acute Promyelocytic Leukemia. Journal of Pediatric Hematology/Oncology, 2014, 36, e546-e548.	0.3	3
423	Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies. Hematology American Society of Hematology Education Program, 2015, 2015, 507-513.	0.9	28
424	Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer. Journal of Internal Medicine, 2015, 278, 627-642.	2.7	31
425	Acute promyelocytic leukemia harbouring rare FLT3-TKD and WT1 mutations: A case report. Oncology Letters, 2015, 10, 1858-1862.	0.8	2
426	Arsenic trioxide alters the differentiation of mouse embryonic stem cell into cardiomyocytes. Scientific Reports, 2015, 5, 14993.	1.6	20
427	The role of NF-Î²B in PARP-inhibitor-mediated sensitization and detoxification of arsenic trioxide in hepatocellular carcinoma cells. Journal of Toxicological Sciences, 2015, 40, 349-363.	0.7	15
428	Identification of a Novel Fusion Gene,IRF2BP2-RARA, in Acute Promyelocytic Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 19-22.	2.3	46
429	Fighting against hematological malignancy in China: from unique system to global impact. Science China Life Sciences, 2015, 58, 1183-1190.	2.3	11
430	Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with <scp>ATRA</scp> and chemotherapy. American Journal of Hematology, 2015, 90, E181-2.	2.0	2
431	Enhanced Anticancer Cells Effects of Optimized Suspension Stable As₂O₃â€Loaded Poly(lacticâ€coâ€glycolic acid) Nanocapsules. Chinese Journal of Chemistry, 2015, 33, 777-784.	2.6	4
432	Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology. Cancer Control, 2015, 22, 158-166.	0.7	16
433	The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia. The Cochrane Library, 2015, , CD010432.	1.5	28
434	Economic evaluation of arsenic trioxide compared to allâ€trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. European Journal of Haematology, 2015, 95, 218-229.	1.1	2
435	Consolidation therapy of arsenic trioxide alternated with chemotherapy achieves remarkable efficacy in newly diagnosed acute promyelocytic leukemia. OncoTargets and Therapy, 2015, 8, 3297.	1.0	7
436	Lithium Chloride Promotes Apoptosis in Human Leukemia NB4 Cells by Inhibiting Glycogen Synthase Kinase-3 Beta. International Journal of Medical Sciences, 2015, 12, 805-810.	1.1	32
437	The impact of Tegillarca granosa extract haishengsu on HL-60 cell. Open Medicine (Poland), 2015, 10, 329-334.	0.6	0

#	Article	IF	Citations
438	The clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma. OncoTargets and Therapy, 2015, 8, 775.	1.0	7
439	Perspective on Therapeutic Strategies of Leukemia Treatment â€" Focus on Arsenic Compounds. , 2015, , .		0
440	Identification of Arsenic Direct-Binding Proteins in Acute Promyelocytic Leukaemia Cells. International Journal of Molecular Sciences, 2015, 16, 26871-26879.	1.8	16
441	Pro-Oxidant Activity of Amine-Pyridine-Based Iron Complexes Efficiently Kills Cancer and Cancer Stem-Like Cells. PLoS ONE, 2015, 10, e0137800.	1.1	28
442	Retinoids: Nutritional, Cellular, and Pharmacological Roles of the Vitamin A Derivatives. , 2015, , .		0
443	Vitamin A, Cancer Treatment and Prevention: The New Role of Cellular Retinol Binding Proteins. BioMed Research International, 2015, 2015, 1-14.	0.9	109
444	Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (APL)). The Cochrane Library, 2015, , .	1.5	7
445	Oral lesions presenting as an early sign of acute leukaemia. BMJ Case Reports, 2015, 2015, bcr2014205100-bcr2014205100.	0.2	4
446	Arsenic trioxide binding to serum proteins. Journal of Photochemistry and Photobiology B: Biology, 2015, 148, 31-36.	1.7	17
447	Induction of human leukemia cell differentiation via PKC/MAPK pathways by arsantin, a sesquiterpene lactone from Artemisia santolina. Archives of Pharmacal Research, 2015, 38, 2020-2028.	2.7	10
449	PML/RARÎ±-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Cancer Research, 2015, 75, 3411-3424.	0.4	39
450	Regulation of Cellular Identity in Cancer. Developmental Cell, 2015, 35, 674-684.	3.1	76
451	Delphinidin induces cytotoxicity and potentiates cytocidal effect in combination with arsenite in an acute promyelocytic leukemia NB4 cell line. Oncology Reports, 2015, 34, 431-438.	1.2	21
452	Reprogramming and Stemness. Perspectives in Biology and Medicine, 2015, 58, 229-246.	0.3	6
453	Prohibitin promotes apoptosis of promyelocytic leukemia induced by arsenic sulfide. International Journal of Oncology, 2015, 47, 2286-2295.	1.4	8
454	Retinoic acid receptors: From molecular mechanisms to cancer therapy. Molecular Aspects of Medicine, 2015, 41, 1-115.	2.7	284
455	FLT3-ITD in acute promyelocytic leukemia: Clinical distinct profile but still controversial prognosis. Leukemia Research, 2015, 39, 397-399.	0.4	20
456	Novel function of PITH domain-containing 1 as an activator of internal ribosomal entry site to enhance RUNX1 expression and promote megakaryocyte differentiation. Cellular and Molecular Life Sciences, 2015, 72, 821-832.	2.4	13

#	Article	IF	Citations
457	Doseâ€adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure. European Journal of Haematology, 2015, 95, 331-335.	1.1	11
458	Correlation between FLT3â€"ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias. Leukemia Research, 2015, 39, 131-137.	0.4	24
459	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Reports, 2015, 16, 280-296.	2.0	200
460	Real-Time Monitoring of Arsenic Trioxide Release and Delivery by Activatable T₁ Imaging. ACS Nano, 2015, 9, 2749-2759.	7.3	106
461	Multivalency in the Inhibition of Oxidative Protein Folding by Arsenic(III) Species. Biochemistry, 2015, 54, 612-621.	1.2	9
462	Long-term follow-up of homoharringtonine plus all-trans retinoic acid-based induction and consolidation therapy in newly diagnosed acute promyelocytic leukemia. International Journal of Hematology, 2015, 101, 279-285.	0.7	7
463	Reprogramming of human cancer cells to pluripotency for models of cancer progression. EMBO Journal, 2015, 34, 739-747.	3.5	52
464	Metaphase cytogenetics and single nucleotide polymorphism arrays in myeloid malignancies. Revista Brasileira De Hematologia E Hemoterapia, 2015, 37, 71-72.	0.7	2
465	Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids. Cancer Research, 2015, 75, 2530-2540.	0.4	48
466	Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma. Cancer Letters, 2015, 366, 112-122.	3.2	21
467	Antitumor effect and underlying mechanism of RGD-modified adenovirus mediated IL-24 expression on myeloid leukemia cells. International Immunopharmacology, 2015, 28, 560-570.	1.7	5
468	Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: A TRAnsition to targeted therapies. British Journal of Cancer, 2015, 112, 413-418.	2.9	21
469	A novel clonal t(1;4)(p36.1;q31) translocation in acute promyelocytic leukaemia. Journal of Clinical Pathology, 2015, 68, 391-393.	1.0	0
470	Targeted Synergism Effects of the Combined Active Constituents of Yinchenhao Tang. , 2015, , 261-282.		0
471	Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer Journal, 2015, 5, e304-e304.	2.8	211
472	Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation. Seminars in Hematology, 2015, 52, 200-206.	1.8	28
473	Hemorrhage and thrombosis in acute promyelocytic leukemia: Can we currently predict these manifestations?. Thrombosis Research, 2015, 135, 573-574.	0.8	2
474	Oridonin stabilizes retinoic acid receptor alpha through ROS-activated NF-Î°B signaling. BMC Cancer, 2015, 15, 248.	1.1	21

#	Article	IF	Citations
475	Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance. Advances in Cancer Research, 2015, 127, 191-226.	1.9	13
476	Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia, 2015, 29, 1084-1091.	3.3	70
477	Toward Individualized Therapy in Acute Myeloid Leukemia. JAMA Oncology, 2015, 1, 820.	3.4	47
478	A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia. Leukemia Research, 2015, 39, 1172-1177.	0.4	10
479	Acute Promyelocytic Leukemia: A Review and Discussion of Variant Translocations. Archives of Pathology and Laboratory Medicine, 2015, 139, 1308-1313.	1.2	94
480	Dose-dependent effects of selenite (Se4+) on arsenite (As3+)-induced apoptosis and differentiation in acute promyelocytic leukemia cells. Cell Death and Disease, 2015, 6, e1596-e1596.	2.7	21
481	Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy. Leukemia Research, 2015, 39, 938-944.	0.4	37
482	Agonist antibody that induces human malignant cells to kill one another. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6158-E6165.	3.3	16
483	Targeting Transcription Factors in Cancer. Trends in Cancer, 2015, 1, 53-65.	3.8	247
484	Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARÎ± and PLZF-RARÎ±â€“Driven Leukemia. Clinical Cancer Research, 2015, 21, 3685-3694.	3.2	40
485	Arsenic Trioxide Negatively Affects Echinococcus granulosus. Antimicrobial Agents and Chemotherapy, 2015, 59, 6946-6951.	1.4	11
486	Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?. Lancet Oncology, The, 2015, 16, 1274-1275.	5.1	4
487	Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 816-819.	0.2	2
488	Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia. Rare Cancers and Therapy, 2015, 3, 119-132.	0.2	6
489	Prognostic importance of expression of the Wilmsâ€™ tumor 1 gene in newly diagnosed acute promyelocytic leukemia. Leukemia and Lymphoma, 2015, 56, 2289-2295.	0.6	13
490	Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling. Leukemia, 2015, 29, 157-168.	3.3	25
491	PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair. Chemico-Biological Interactions, 2015, 226, 12-22.	1.7	28
492	Oxidative stress, redox regulation and diseases of cellular differentiation. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 1607-1621.	1.1	188

#	Article	IF	Citations
493	The protein kinase C agonist prostratin induces differentiation of human myeloid leukemia cells and enhances cellular differentiation by chemotherapeutic agents. Cancer Letters, 2015, 356, 686-696.	3.2	23
494	Progress in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 139-151.	0.2	40
496	Impact of an Alert System on Quality Indicators in Patients With Acute Promyelocytic Leukemia. Clinical Journal of Oncology Nursing, 2016, 20, 523-527.	0.3	2
497	Single-Cell Sequencing Technology in Oncology: Applications for Clinical Therapies and Research. Analytical Cellular Pathology, 2016, 2016, 1-8.	0.7	5
498	Continued importance in translation from research to health policy in China. Journal of Translational Medicine, 2016, 14, 272.	1.8	1
499	Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia. PLoS ONE, 2016, 11, e0147545.	1.1	10
500	All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis. PLoS ONE, 2016, 11, e0158760.	1.1	33
501	Optimal treatment strategies for high-risk acute promyelocytic leukemia. Current Opinion in Hematology, 2016, 23, 127-136.	1.2	19
502	NLS-RARÎ± modulates acute promyelocytic leukemia NB4 cell proliferation and differentiation via the PI3K/AKT pathway. Molecular Medicine Reports, 2016, 14, 5495-5500.	1.1	4
503	Transcriptomics and proteomics in studies of induced differentiation of leukemia cells. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2016, 10, 122-137.	0.2	0
504	A complex translocation (3;17;15) in acute promyelocytic leukemia confirmed by fluorescence in situ hybridization. Oncology Letters, 2016, 12, 4717-4719.	0.8	3
505	In vitro effect of sodium arsenite on Echinococcus granulosus protoscoleces. Molecular and Biochemical Parasitology, 2016, 207, 49-55.	0.5	12
506	LukS-PV induces differentiation by activating the ERK signaling pathway and c-JUN/c-FOS in human acute myeloid leukemia cells. International Journal of Biochemistry and Cell Biology, 2016, 76, 107-114.	1.2	12
507	Hematological Practice in Hong Kong and China. Hematology/Oncology Clinics of North America, 2016, 30, 445-456.	0.9	1
508	pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment inÂvitro and inÂvivo. Journal of Biomaterials Applications, 2016, 31, 23-35.	1.2	44
509	Current management of newly diagnosed acute promyelocytic leukemia. Annals of Oncology, 2016, 27, 1474-1481.	0.6	116
510	The blind men and the AML elephant: can we feel the progress?. Blood Cancer Journal, 2016, 6, e424-e424.	2.8	6
511	Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid. Blood, 2016, 127, 458-463.	0.6	40

#	Article	IF	Citations
512	Bloodâ€™s 70th anniversary: arsenicâ€”from poison pill to magic bullet. Blood, 2016, 127, 1729-1730.	0.6	7
513	Acute promyelocytic leukemia with the translocation t(15;17)(q22;q21) associated with t(1;2)(q42~43;q11.2~12): a case report. Journal of Medical Case Reports, 2016, 10, 203.	0.4	8
514	In silicoframeworks for systematic pre-clinical screening of potential anti-leukemia therapeutics. Expert Opinion on Drug Discovery, 2016, 11, 1213-1222.	2.5	3
515	Thiolated arsenicals in arsenic metabolism: Occurrence, formation, and biological implications. Journal of Environmental Sciences, 2016, 49, 59-73.	3.2	61
516	Acute myeloid leukemia in children: Current status and future directions. Pediatrics International, 2016, 58, 71-80.	0.2	71
517	Biomarkers of Nutrition for Development (BOND)â€”Vitamin A Review. Journal of Nutrition, 2016, 146, 1816S-1848S.	1.3	317
518	Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. Epigenomics, 2016, 8, 945-957.	1.0	21
519	Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells. Scientific Reports, 2016, 6, 31009.	1.6	33
520	A High Throughput Phenotypic Screening reveals compounds that counteract premature osteogenic differentiation of HGPS iPS-derived mesenchymal stem cells. Scientific Reports, 2016, 6, 34798.	1.6	28
521	A Rare Occurrence of Simultaneous Venous and Arterial Thromboembolic Events â€“ Lower Limb Deep Venous Thrombosis and Pulmonary Thromboembolism as Initial Presentation in Acute Promyelocytic Leukemia. Clinical Medicine Insights: Oncology, 2016, 10, CMO.S37866.	0.6	3
522	From molecular interaction to acute promyelocytic leukemia: Calculating leukemogenesis and remission from endogenous molecular-cellular network. Scientific Reports, 2016, 6, 24307.	1.6	18
523	Alternol inhibits the proliferation and induces the differentiation of the mouse melanoma B16F0 cell line. Oncology Reports, 2016, 36, 1150-1156.	1.2	2
524	Native musk and synthetic musk ketone strongly induced the growth repression and the apoptosis of cancer cells. BMC Complementary and Alternative Medicine, 2016, 16, 511.	3.7	18
525	Current standard treatment of adult acute promyelocytic leukaemia. British Journal of Haematology, 2016, 172, 841-854.	1.2	60
526	AFM force indentation analysis on leukemia cells. Analytical Methods, 2016, 8, 4421-4431.	1.3	10
527	The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nature Reviews Cancer, 2016, 16, 463-478.	12.8	209
528	PU.1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation. Journal of Hematology and Oncology, 2016, 9, 44.	6.9	46
529	Changes of Apolipoprotein M Gene Expression During the Cell Differentiation and Apoptosis Induced by Simvastatin in Combination with All-Trans Retinoic Acid in Human Promyelocytic Leukemia Cell Line NB4. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 54-61.	0.3	1

#	Article	IF	Citations
530	Tamoxifen enhances the differentiation-inducing and growth-inhibitory effects of all-trans retinoic acid in acute promyelocytic leukemia cells. International Journal of Oncology, 2016, 48, 1095-1102.	1.4	6
531	Nanostructured materials functionalized with metal complexes: In search of alternatives for administering anticancer metallodrugs. Coordination Chemistry Reviews, 2016, 312, 67-98.	9.5	183
532	Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia. Cancer Cell, 2016, 29, 32-48.	7.7	153
533	Natural Product Vibsanin A Induces Differentiation of Myeloid Leukemia Cells through PKC Activation. Cancer Research, 2016, 76, 2698-2709.	0.4	27
534	IDH mutations in cancer and progress toward development of targeted therapeutics. Annals of Oncology, 2016, 27, 599-608.	0.6	367
535	RIG-G inhibits the proliferation of NB4 cells and propels ATRA-induced differentiation of APL cells. Leukemia Research, 2016, 40, 83-89.	0.4	5
536	A facile route to coreâ€“shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment. Nanoscale, 2016, 8, 4373-4380.	2.8	30
537	Leukaemia 'firsts' in cancer research and treatment. Nature Reviews Cancer, 2016, 16, 163-172.	12.8	67
538	LG-362B targets PML-RARÎ± and blocks ATRA resistance of acute promyelocytic leukemia. Leukemia, 2016, 30, 1465-1474.	3.3	19
539	Tanshinone IIA inhibits acute promyelocytic leukemia cell proliferation and induces their apoptosis in vivo. Blood Cells, Molecules, and Diseases, 2016, 56, 46-52.	0.6	23
540	Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989â€“2012. Leukemia, 2016, 30, 24-31.	3.3	68
541	Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia. Journal of Oncology Pharmacy Practice, 2016, 22, 646-651.	0.5	5
542	RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma. International Journal of Pharmaceutics, 2017, 519, 250-262.	2.6	70
544	Cancer as robust intrinsic state shaped by evolution: a key issues review. Reports on Progress in Physics, 2017, 80, 042701.	8.1	58
545	Cytotoxicity and genotoxicity effects of arsenic trioxide on SQ20B human laryngeal carcinoma cells. Experimental and Toxicologic Pathology, 2017, 69, 349-358.	2.1	1
546	Inducing cell proliferative prevention in human acute promyelocytic leukemia by miR-182 inhibition through modulation of CASP9 expression. Biomedicine and Pharmacotherapy, 2017, 89, 1152-1158.	2.5	9
547	Inorganic arsenic inhibits the nucleotide excision repair pathway and reduces the expression of XPC. DNA Repair, 2017, 52, 70-80.	1.3	27
548	Transcriptional Addiction in Cancer. Cell, 2017, 168, 629-643.	13.5	843

#	Article	IF	Citations
549	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. Cancer Discovery, 2017, 7, 478-493.	7.7	350
550	Chemotherapy for Leukemia. , 2017, , .		2
551	All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells. Cell Death and Disease, 2017, 8, e2782-e2782.	2.7	15
552	Deguelin induced differentiation of mutated NPM1 acute myeloid leukemia in vivo and in vitro. Anti-Cancer Drugs, 2017, 28, 723-738.	0.7	8
553	Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis. Hematology, 2017, 22, 1-10.	0.7	4
554	Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation. Experimental Hematology, 2017, 52, 12-23.	0.2	36
555	Cancer Cytogenetics. Methods in Molecular Biology, 2017, , .	0.4	4
556	A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells. Molecular Cancer Therapeutics, 2017, 16, 273-284.	1.9	80
557	Recurrent Cytogenetic Abnormalities in Acute Myeloid Leukemia. Methods in Molecular Biology, 2017, 1541, 223-245.	0.4	26
558	Arsenite Binds to the RING Finger Domain of FANCL E3 Ubiquitin Ligase and Inhibits DNA Interstrand Crosslink Repair. ACS Chemical Biology, 2017, 12, 1858-1866.	1.6	21
559	The novel Indole-3-formaldehyde (2-AITFEI-3-F) is involved in processes of apoptosis induction?. Life Sciences, 2017, 181, 31-44.	2.0	19
561	APL: Oh! What a tangled web we weave. Blood, 2017, 129, 1744-1745.	0.6	0
562	The classical nature of distinctive CMML monocytes. Blood, 2017, 129, 1745-1746.	0.6	9
563	Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents. Annual Review of Cancer Biology, 2017, 1, 379-401.	2.3	14
564	Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?. Leukemia and Lymphoma, 2017, 58, 1743-1746.	0.6	5
565	Microparticles and Fibrinolysis. Seminars in Thrombosis and Hemostasis, 2017, 43, 129-134.	1.5	34
566	FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA Demethylase. Cancer Cell, 2017, 31, 127-141.	7.7	1,139
567	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 2017, 129, 1275-1283.	0.6	214

#	Article	IF	Citations
568	Zinc Depletion by TPEN Induces Apoptosis in Human Acute Promyelocytic NB4 Cells. Cellular Physiology and Biochemistry, 2017, 42, 1822-1836.	1.1	37
569	The autophagy scaffold protein ALFY is critical for the granulocytic differentiation of AML cells. Scientific Reports, 2017, 7, 12980.	1.6	15
570	Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 889-896.e5.	0.2	4
571	Lentivirus-mediated RIG-I knockdown relieves cell proliferation inhibition, cell cycle arrest and apoptosis in ATRA-induced NB4 cells via the AKT-FOXO3A signaling pathway in vitro. Molecular Medicine Reports, 2017, 16, 2556-2562.	1.1	1
572	Synthesis and evaluation of biological activities of vibsanin A analogs. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4536-4539.	1.0	13
573	Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide. Annals of Hematology, 2017, 96, 2005-2013.	0.8	17
574	Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia. Cancer Cell, 2017, 32, 324-341.e6.	7.7	179
575	PML-RARÎ± stabilized by zinc in human acute promyelocytic leukemia NB4 cells. Journal of Inorganic Biochemistry, 2017, 175, 92-100.	1.5	10
576	Malaria, Epsteinâ€“Barr virus infection and the pathogenesis of Burkitt's lymphoma. International Journal of Cancer, 2017, 141, 1849-1855.	2.3	25
577	Shikonin suppresses proliferation and induces apoptosis in human leukemia NB4 cells through modulation of MAPKs and c-Myc. Molecular Medicine Reports, 2017, 16, 3055-3060.	1.1	24
578	Therapy-related myelodysplastic syndrome after successful treatment of acute promyelocytic leukemia: case report and literature review. Romanian Journal of Laboratory Medicine, 2017, 25, 165-179.	0.1	3
579	Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. Cancer Cell, 2017, 32, 552-560.	7.7	219
580	Cancer stem cells and differentiation therapy. Tumor Biology, 2017, 39, 101042831772993.	0.8	76
581	Acute Promyelocytic Leukemia: A Perspective. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 543-544.	0.2	14
582	HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells. Journal of Pharmaceutical and Biomedical Analysis, 2017, 145, 356-363.	1.4	29
583	Cure modeling in real-time prediction: How much does it help?. Contemporary Clinical Trials, 2017, 59, 30-37.	0.8	4
584	PML-RARA mutations confer varying arsenic trioxide resistance. Protein and Cell, 2017, 8, 296-301.	4.8	3
585	The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death and Differentiation, 2017, 24, 212-224.	5.0	180

#	Article	IF	Citations
586	Activation of G0S2 is coordinated by recruitment of PML/RARÎ± and C/EBPÎµ to its promoter during ATRA-induced APL differentiation. Journal of Leukocyte Biology, 2017, 101, 655-664.	1.5	4
587	Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Nonâ€“High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. Journal of Clinical Oncology, 2017, 35, 605-612.	0.8	299
588	Acute lymphoblastic leukemia: a genomic perspective. BoletÃn MÃ©dico Del Hospital Infantil De MÃ©xico (English Edition), 2017, 74, 13-26.	0.0	3
589	Hepatocellular carcinoma complicated by acute promyelocytic leukemia: a case report. Acta Hepatologica Japonica, 2017, 58, 176-182.	0.0	0
590	Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFÎºB-dependent differentiation of AML cells. Blood Advances, 2017, 1, 2046-2057.	2.5	35
591	Verteporfin Inhibits Cell Proliferation and Induces Apoptosis in Human Leukemia NB4 Cells without Light Activation. International Journal of Medical Sciences, 2017, 14, 1031-1039.	1.1	17
592	Biological effects and epidemiological consequences of arsenic exposure, and reagents that can ameliorate arsenic damage in vivo. Oncotarget, 2017, 8, 57605-57621.	0.8	55
593	Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy. OncoTargets and Therapy, 2017, Volume 10, 2305-2313.	1.0	13
594	Acute WT1-positive promyelocytic leukemia with hypogranular variant morphology, bcr-3 isoform of PML-RARÎ± and Flt3-ITD mutation: a rare case report. Sao Paulo Medical Journal, 2017, 135, 179-184.	0.4	4
595	Drug Repurposing for the Treatment of Acute Myeloid Leukemia. Frontiers in Medicine, 2017, 4, 211.	1.2	28
596	Targeting TRIB3 and PML-RARÎ± interaction against APL. Oncotarget, 2017, 8, 52012-52013.	0.8	2
597	Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. OncoTargets and Therapy, 2017, Volume 10, 1585-1601.	1.0	66
598	Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia â€“ identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer, 2017, 17, 630.	1.1	18
599	A Case of Acute Promyelocytic Leukemia with Co-existence of BCR-ABL1 and PML-RARA Rearrangements Detected by PCR. Laboratory Medicine Online, 2017, 7, 196.	0.0	3
600	Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. Hematology American Society of Hematology Education Program, 2017, 2017, 37-44.	0.9	49
601	Recent advances in acute promyelocytic leukaemia. F1000Research, 2017, 6, 1273.	0.8	17
602	RXRÎ± ligand Z-10 induces PML-RARÎ± cleavage and APL cell apoptosis through disrupting PML-RARÎ±/RXRÎ± complex in a cAMP-independent manner. Oncotarget, 2017, 8, 12311-12322.	0.8	6
603	Influence of acute promyelocytic leukemia therapeutic drugs on nuclear pore complex density and integrity. Biochemical and Biophysical Research Communications, 2018, 499, 570-576.	1.0	2

#	Article	IF	Citations
604	Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance. Molecular Cancer Research, 2018, 16, 1263-1274.	1.5	12
605	Toxic effects of arsenic trioxide on <italic>Echinococcus granulosus</italic> protoscoleces through ROS production, and Ca²⁺-ER stress-dependent apoptosis. Acta Biochimica Et Biophysica Sinica, 2018, 50, 579-585.	0.9	15
606	Arsenic trioxide: insights into its evolution to an anticancer agent. Journal of Biological Inorganic Chemistry, 2018, 23, 313-329.	1.1	100
607	Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA. Leukemia Research, 2018, 66, 85-88.	0.4	4
609	Vibsanol A induces differentiation of acute myeloid leukemia cells via activation of the PKC signaling pathway and induction of ROS. Leukemia and Lymphoma, 2018, 59, 2414-2422.	0.6	2
610	Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy. Cell Death and Disease, 2018, 9, 75.	2.7	32
611	Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the firstâ€line treatment of adult acute promyelocytic leukemia. European Journal of Haematology, 2018, 100, 344-350.	1.1	10
612	The clinical significance of FLT3 ITD mutation on the prognosis of adult acute promyelocytic leukemia. Hematology, 2018, 23, 379-384.	0.7	11
613	Silencing of HMGA2 reverses retardance of cell differentiation in human myeloid leukaemia. British Journal of Cancer, 2018, 118, 405-415.	2.9	12
614	Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood, 2018, 131, 2698-2711.	0.6	66
615	Cure of APL Without Chemotherapy. , 2018, , 133-151.		0
616	Minimal Residual Disease in APL. , 2018, , 153-161.		0
617	Treatment of Refractory and Relapsed APL. , 2018, , 163-170.		0
618	From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia. Clinical Medicine, 2018, 18, s47-s53.	0.8	9
619	Mechanisms and management of coagulopathy in acute promyelocytic leukemia. Thrombosis Research, 2018, 164, S82-S88.	0.8	32
620	Special Situations in APL. , 2018, , 203-210.		0
621	APL in Developing Countries: A Chemotherapy-Based Approach. , 2018, , 211-216.		0
622	APL in Developing Countries: ATO-Based Approach. , 2018, , 217-229.		0

#	Article	IF	Citations
623	Rare Acute Leukemia Variants Involving Retinoic Acid Receptor Genes. , 2018, , 243-255.		0
624	Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy. Modern Pathology, 2018, 31, 1318-1331.	2.9	9
625	LRRC25 plays a key role in all-trans retinoic acid-induced granulocytic differentiation as a novel potential leukocyte differentiation antigen. Protein and Cell, 2018, 9, 785-798.	4.8	5
626	Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Seminars in Cancer Biology, 2018, 48, 36-52.	4.3	181
627	The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. Leukemia Research, 2018, 65, 14-19.	0.4	21
628	Endogenous Molecular-Cellular Network Cancer Theory: A Systems Biology Approach. Methods in Molecular Biology, 2018, 1702, 215-245.	0.4	5
629	Frontline therapy of acute promyelocytic leukemia: Randomized comparison of <scp>ATRA</scp> and intensified chemotherapy versus <scp>ATRA</scp> and anthracyclines. European Journal of Haematology, 2018, 100, 154-162.	1.1	6
630	Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia. Oncotarget, 2018, 9, 25647-25660.	0.8	13
631	Treatment of Acute Promyelocytic Leukemia With No or Minimal Chemotherapy: Now a Reality in Common Clinical Practice. Journal of Oncology Practice, 2018, 14, 663-664.	2.5	3
632	Hyperfibrinolysis Is an Important Cause of Early Hemorrhage in Patients with Acute Promyelocytic Leukemia. Medical Science Monitor, 2018, 24, 3249-3255.	0.5	5
634	Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)). The Cochrane Library, 2018, 2018, CD011960.	1.5	17
635	BRD4 interacts with PML/RARÎ± in acute promyelocytic leukemia. Frontiers of Medicine, 2018, 12, 726-734.	1.5	2
636	Acute Promyelocytic Leukemia. Journal of Nepal Paediatric Society, 2018, 37, 270-272.	0.1	1
637	The novel threeâ€'way variant t(6;17;15)(p21;q21;q22) in acute promyelocytic leukemia with an FLT3â€'ITD mutation: A case report. Oncology Letters, 2018, 16, 6121-6125.	0.8	1
638	Nanodiamond autophagy inhibitor allosterically improves the arsenical-based therapy of solid tumors. Nature Communications, 2018, 9, 4347.	5.8	77
639	Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations. PLoS Genetics, 2018, 14, e1007642.	1.5	3
640	Regulation of cell surface protease receptor S100A10 by retinoic acid therapy in acute promyelocytic leukemia (APL)â˜†. Cell Death and Disease, 2018, 9, 920.	2.7	13
641	Acute promyelocytic leukemia in the intensive care unit: A retrospective analysis. Leukemia Research, 2018, 73, 41-43.	0.4	2

#	Article	IF	Citations
642	The developmental origin of brain tumours: a cellular and molecular framework. Development (Cambridge), 2018, 145, .	1.2	97
643	Acute Promyelocytic Leukemia. , 2018, , .		2
645	Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia. International Journal of Hematology, 2018, 108, 274-281.	0.7	3
646	Tissue clearing of both hard and soft tissue organs with the PEGASOS method. Cell Research, 2018, 28, 803-818.	5.7	256
647	Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. Cancer Chemotherapy and Pharmacology, 2018, 82, 229-236.	1.1	15
648	Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells. Molecular Cancer Therapeutics, 2018, 17, 1871-1880.	1.9	25
649	Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo. Cancer Letters, 2018, 433, 117-130.	3.2	19
650	How to eliminate MYCN-positive hepatic cancer stem cells to prevent the recurrence?. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6388-E6389.	3.3	5
651	Genomeâ€‘wide profiling of lncRNA expression patterns in patients with acute promyelocytic leukemia with differentiation therapy. Oncology Reports, 2018, 40, 1601-1613.	1.2	5
652	Targeted therapy for fusion-driven high-risk acute leukemia. Blood, 2018, 132, 1241-1247.	0.6	22
653	Cell Cycle Arrest and Apoptosis Induction Activity of Nitidine Chloride on Acute Myeloid Leukemia Cells. Medicinal Chemistry, 2018, 14, 60-66.	0.7	14
654	Salinomycin induces apoptosis and differentiation in human acute promyelocytic leukemia cells. Oncology Reports, 2018, 40, 877-886.	1.2	12
655	Acute Myeloid Leukemia in Children. , 2018, , 981-993.		1
656	Bradycardia during Induction Therapy with All-trans Retinoic Acid in Patients with Acute Promyelocytic Leukemia: Case Report and Literature Review. Case Reports in Hematology, 2018, 2018, 1-6.	0.3	5
657	What has traditional Chinese medicine delivered for modern medicine?. Expert Reviews in Molecular Medicine, 2018, 20, e4.	1.6	198
658	Proteomic Profiling of HL-60 Cells during ATRA-Induced Differentiation. Bulletin of Experimental Biology and Medicine, 2018, 165, 530-543.	0.3	2
659	JMJD3 facilitates C/EBPÎ²-centered transcriptional program to exert oncorepressor activity in AML. Nature Communications, 2018, 9, 3369.	5.8	51
660	Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nature Communications, 2018, 9, 3069.	5.8	116

#	Article	IF	Citations
661	Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 871-879.	5.1	110
662	Understanding Molecular Pathogenesis. , 2018, , 231-242.		1
663	Molecular Basis of Lymphoid and Myeloid Diseases. , 2018, , 299-328.		2
664	Modulating Cell Fate as a Therapeutic Strategy. Cell Stem Cell, 2018, 23, 329-341.	5.2	40
665	Organic Arsenicals as Functional Motifs in Polymer and Biomaterials Science. Macromolecular Rapid Communications, 2018, 39, 1800205.	2.0	11
666	2-Bromopalmitate targets retinoic acid receptor alpha and overcomes all-trans retinoic acid resistance of acute promyelocytic leukemia. Haematologica, 2019, 104, 102-112.	1.7	10
667	Factors Affecting Early Death and Survival of Patients With Acute Promyelocytic Leukemia Treated With ATRA-Based Therapy Regimens. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e63-e70.	0.2	13
668	Genetic and Epigenetic Profiling in Personalized Medicine: Advances in Treatment of Acute Myeloid Leukemia. Europeanization and Globalization, 2019, , 341-374.	0.1	0
669	PML Bodies in Mitosis. Cells, 2019, 8, 893.	1.8	20
670	Personalized Medicine in Healthcare Systems. Europeanization and Globalization, 2019, , .	0.1	2
671	The Role of Abnormal Hemostasis and Fibrinolysis in Morbidity and Mortality of Acute Promyelocytic Leukemia. Seminars in Thrombosis and Hemostasis, 2019, 45, 612-621.	1.5	31
672	All-Trans Retinoic Acid Impairs Platelet Function and Thrombus Formation and Inhibits Protein Kinase CÃŸI/Î´ Phosphorylation. Thrombosis and Haemostasis, 2019, 119, 1655-1664.	1.8	12
673	Modeling dynamics and alternative treatment strategies in acute promyelocytic leukemia. PLoS ONE, 2019, 14, e0221011.	1.1	3
674	Pharmacological properties of Rheum turkestanicum Janisch. Heliyon, 2019, 5, e01986.	1.4	13
675	Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide. American Journal of Clinical Pathology, 2019, 152, 675-685.	0.4	2
676	ZnAs@SiO₂ nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling. Theranostics, 2019, 9, 4391-4408.	4.6	52
677	Beyond cisplatin: Combination therapy with arsenic trioxide. Inorganica Chimica Acta, 2019, 496, 119030.	1.2	20
678	TRIB3 Stabilizes High TWIST1 Expression to Promote Rapid APL Progression and ATRA Resistance. Clinical Cancer Research, 2019, 25, 6228-6242.	3.2	21

#	Article	IF	Citations
679	Current and emerging treatments for acute promyelocytic leukemia. Expert Opinion on Orphan Drugs, 2019, 7, 453-461.	0.5	1
680	Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Childrenâ€™s Hospital APL 2005 protocol (BCH-APL 2005). Pediatric Hematology and Oncology, 2019, 36, 399-409.	0.3	7
681	Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells, 2019, 8, 1229.	1.8	18
682	Isoliquiritigenin, an Orally Available Natural FLT3 Inhibitor from Licorice, Exhibits Selective Antiâ€“Acute Myeloid Leukemia Efficacy In Vitro and In Vivo. Molecular Pharmacology, 2019, 96, 589-599.	1.0	8
683	Anti-leukemic effects of simvastatin on NRASG12D mutant acute myeloid leukemia cells. Molecular Biology Reports, 2019, 46, 5859-5866.	1.0	12
684	A dual functional ruthenium arene complex induces differentiation and apoptosis of acute promyelocytic leukemia cells. Chemical Science, 2019, 10, 9721-9728.	3.7	10
685	The Impact of Flt3 Gene Mutations in Acute Promyelocytic Leukemia: A Meta-Analysis. Cancers, 2019, 11, 1311.	1.7	33
686	Sodium Arsenite Inhibits Lung Fibroblast Differentiation and Pulmonary Fibrosis. Pharmacology, 2019, 104, 368-376.	0.9	4
687	The factors affecting early death in newly diagnosed APL patients. Open Medicine (Poland), 2019, 14, 647-652.	0.6	19
688	NEMO: cancer subtyping by integration of partial multi-omic data. Bioinformatics, 2019, 35, 3348-3356.	1.8	141
689	Effect of continuous venovenous haemodialysis on outcome and pharmacokinetics of arsenic species in a patient with acute promyelocytic leukaemia and acute kidney injury. British Journal of Clinical Pharmacology, 2019, 85, 849-853.	1.1	3
690	Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse. Proteomics - Clinical Applications, 2019, 13, 1800133.	0.8	7
691	Imaging Flow Cytometric Analysis of Stilbene-Dependent Apoptosis in Drug Resistant Human Leukemic Cell Lines. Molecules, 2019, 24, 1896.	1.7	14
692	Precision Medicine in Cancer Therapy. Cancer Treatment and Research, 2019, , .	0.2	4
693	The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers. Cancer Treatment and Research, 2019, 178, 81-108.	0.2	2
694	The Pleiotropic Role of Retinoic Acid/Retinoic Acid Receptors Signaling: From Vitamin A Metabolism to Gene Rearrangements in Acute Promyelocytic Leukemia. International Journal of Molecular Sciences, 2019, 20, 2921.	1.8	16
695	Medication related osteonecrosis of jaw in a leukemia patient undergoing systemic arsenic trioxide therapy: A rare case report. Oral Oncology, 2019, 99, 104343.	0.8	5
696	Leukemic ILâ€17RB signaling regulates leukemic survival and chemoresistance. FASEB Journal, 2019, 33, 9565-9576.	0.2	7

#	Article	IF	Citations
697	The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood, 2019, 134, 597-605.	0.6	95
698	Optimisation of Folate-Mediated Liposomal Encapsulated Arsenic Trioxide for Treating HPV-Positive Cervical Cancer Cells In Vitro. International Journal of Molecular Sciences, 2019, 20, 2156.	1.8	17
699	Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARÎ± fusion protein at a glance. Seminars in Oncology, 2019, 46, 133-144.	0.8	16
700	Treating leukemia: differentiation therapy for mIDH2 AML. Cell Research, 2019, 29, 427-428.	5.7	1
701	Real life outcomes of patients aged â‰¥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. Leukemia and Lymphoma, 2019, 60, 2720-2732.	0.6	2
702	Advances in precision epigenetic treatment for acute promyelocytic leukemia.. Expert Review of Precision Medicine and Drug Development, 2019, 4, 163-178.	0.4	1
703	Epigenetic drug library screening identified an LSD1 inhibitor to target UTX-deficient cells for differentiation therapy. Signal Transduction and Targeted Therapy, 2019, 4, 11.	7.1	17
704	Phenylarsine Oxide Can Induce Degradation of PLZF-RARÎ± Variant Fusion Protein of Acute Promyelocytic Leukemia. Chemical Research in Toxicology, 2019, 32, 548-550.	1.7	4
705	Predictors of early hemorrhage in acute promyelocytic leukemia. Leukemia and Lymphoma, 2019, 60, 2394-2403.	0.6	24
706	Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology. Nutrients, 2019, 11, 627.	1.7	27
707	Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer. American Journal of Physiology - Renal Physiology, 2019, 316, G632-G640.	1.6	13
708	Targeting chromatin complexes in fusion protein-driven malignancies. Nature Reviews Cancer, 2019, 19, 255-269.	12.8	55
709	An extracellular pH-driven targeted multifunctional manganese arsenite delivery system for tumor imaging and therapy. Biomaterials Science, 2019, 7, 2480-2490.	2.6	19
710	Acute Promyelocytic Leukemia: A History over 60 Yearsâ€"From the Most Malignant to the most Curable Form of Acute Leukemia. Oncology and Therapy, 2019, 7, 33-65.	1.0	48
711	Sodium arsenite augments sensitivity of Echinococcus granulosus protoscoleces to albendazole. Experimental Parasitology, 2019, 200, 55-60.	0.5	3
712	Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide. Expert Review of Clinical Pharmacology, 2019, 12, 371-378.	1.3	10
713	Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide. OMICS A Journal of Integrative Biology, 2019, 23, 119-130.	1.0	3
714	EVI1 promotes epithelial-to-mesenchymal transition, cancer stem cell features and chemoâ^'/radioresistance in nasopharyngeal carcinoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 82.	3.5	28

#	Article	IF	Citations
715	Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML. Blood Advances, 2019, 3, 1379-1393.	2.5	15
716	Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index. Scientific Reports, 2019, 9, 16775.	1.6	14
717	Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study. Journal of King Abdulaziz University, Islamic Economics, 2019, 40, 1171-1176.	0.5	3
718	Irreversibility of arsenic trioxide induced PML/RARÎ± fusion protein solubility changes. Metallomics, 2019, 11, 2089-2096.	1.0	6
719	Clinical Trials of Repurposing Medicines in Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass), 2019, 25, 153-163.	1.0	4
720	Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell. Medicine (United States), 2019, 98, e15875.	0.4	13
721	Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 890-899.	3.3	18
722	Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia. Expert Review of Hematology, 2019, 12, 81-87.	1.0	11
723	CXXC5: A novel regulator and coordinator of TGFâ€Î²2, BMP and Wnt signaling. Journal of Cellular and Molecular Medicine, 2019, 23, 740-749.	1.6	39
724	Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia. Leukemia and Lymphoma, 2019, 60, 711-719.	0.6	4
725	Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil â€“ Early Deaths Are StillÂaÂProblem. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e116-e122.	0.2	20
726	Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression. Journal of Cancer Research and Clinical Oncology, 2019, 145, 19-29.	1.2	101
727	EVI-1 modulates arsenic trioxide induced apoptosis through JNK signalling pathway in leukemia cells. Experimental Cell Research, 2019, 374, 140-151.	1.2	5
728	Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-Î°B repressing factor. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2220-2225.	3.3	55
729	Diethyl [(3-phenoxy-2-oxo-4-phenyl-azetidin-1-yl)-phenyl-methyl]-phosphonate as a potent anticancer agent in chemo-differentiation therapy of acute promyelocytic leukemia. European Journal of Pharmacology, 2019, 846, 79-85.	1.7	7
730	RARÎ³-rearrangements resemble acute promyelocytic leukemia and benefit from 3â€‰+â€‰7 regimen. Leukemia and Lymphoma, 2019, 60, 1831-1834.	0.6	13
731	Pharmacokinetic Properties of Arsenic Species after Intravenous and Intragastrical Administration of Arsenic Trioxide Solution in Cynomolgus Macaques Using HPLC-ICP-MS. Molecules, 2019, 24, 241.	1.7	11
732	Curative strategies in APL. Seminars in Hematology, 2019, 56, 131-138.	1.8	6

#	Article	IF	Citations
733	The diagnostic use of ADVIA 2120i Siemens and an â€œAPL criteriaâ€•can help to reduce the rate of early death in the APL. International Journal of Laboratory Hematology, 2019, 41, 124-132.	0.7	5
734	Panoramic view of common fusion genes in a large cohort of Chinese de novo acute myeloid leukemia patients. Leukemia and Lymphoma, 2019, 60, 1071-1078.	0.6	22
735	Childhood Leukemia. , 2020, , 1748-1764.e4.		6
736	Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e382-e391.	0.2	5
737	Identification of chlorprothixene as a potential drug that induces apoptosis and autophagic cell death in acute myeloid leukemia cells. FEBS Journal, 2020, 287, 1645-1665.	2.2	13
738	ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica, 2020, 105, 2286-2297.	1.7	43
739	Caspase-8, receptor-interacting protein kinase 1 (RIPK1), and RIPK3 regulate retinoic acid-induced cell differentiation and necroptosis. Cell Death and Differentiation, 2020, 27, 1539-1553.	5.0	25
740	Outcomes in Adult Acute Promyelocytic Leukemia: A Decade Experience. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e158-e164.	0.2	12
741	Exploring six-coordinate germanium(IV)-diketonate complexes as anticancer agents. Inorganica Chimica Acta, 2020, 503, 119375.	1.2	14
742	The comparison of bone marrow kinetics between patients with acute myeloid leukemia and acute promyelocytic leukemia after induction chemotherapy. Immunopharmacology and Immunotoxicology, 2020, 42, 17-21.	1.1	1
743	Allâ€trans retinoic acid (ATRA)â€induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL). European Journal of Haematology, 2020, 104, 236-250.	1.1	21
744	Early Mortality in Children and Adolescents with Acute Promyelocytic Leukemia: Experience of the Boldrini Childrenâ€™s Center. Journal of Pediatric Hematology/Oncology, 2020, 42, e641-e646.	0.3	10
745	All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase. Cancer Letters, 2020, 473, 130-138.	3.2	5
746	Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. International Journal of Molecular Sciences, 2020, 21, 7437.	1.8	20
747	Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduction and Targeted Therapy, 2020, 5, 228.	7.1	120
748	NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma. Cell Reports, 2020, 31, 107782.	2.9	35
749	Therapeutic Approaches for Acute Promyelocytic Leukaemia: Moving Towards an Orally Chemotherapy-Free Era. Frontiers in Oncology, 2020, 10, 586004.	1.3	7
750	Probing arsenic trioxide (ATO) treated leukemia cell elasticities using atomic force microscopy. Analytical Methods, 2020, 12, 4734-4741.	1.3	1

#	Article	IF	Citations
751	Research on the Potential Mechanism of Gentiopicroside Against Gastric Cancer Based on Network Pharmacology . Drug Design, Development and Therapy, 2020, Volume 14, 5109-5118.	2.0	21
752	A Phase 1 Study of IRX195183, a RARÎ±-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML. Frontiers in Oncology, 2020, 10, 587062.	1.3	3
753	Understanding molecular pathogenesis: the biological basis of human disease and implications for improved treatment of human disease. , 2020, , 191-200.		1
754	Deoxyshikonin Inhibits Viability and Glycolysis by Suppressing the Akt/mTOR Pathway in Acute Myeloid Leukemia Cells. Frontiers in Oncology, 2020, 10, 1253.	1.3	21
755	The Curcumin Analogue, EF-24, Triggers p38 MAPK-Mediated Apoptotic Cell Death via Inducing PP2A-Modulated ERK Deactivation in Human Acute Myeloid Leukemia Cells. Cancers, 2020, 12, 2163.	1.7	18
756	Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. Journal of Biomedical Science, 2020, 27, 81.	2.6	35
757	A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer. Molecular Therapy - Oncolytics, 2020, 18, 215-225.	2.0	22
758	Rosiglitazone binds to RXRÎ± to induce RXRÎ± tetramerization and NB4 cell differentiation. Biochemical and Biophysical Research Communications, 2020, 530, 160-166.	1.0	0
759	Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia. Toxicology and Applied Pharmacology, 2020, 409, 115299.	1.3	29
760	Mapping and targeting of the leukemic microenvironment. Journal of Experimental Medicine, 2020, 217, .	4.2	29
761	Retinoic acid receptor Î³ is a therapeutically targetable driver of growth and survival in prostate cancer. Cancer Reports, 2020, 3, e1284.	0.6	19
762	Emerging Cancer Epigenetic Mechanisms Regulated by All-Trans Retinoic Acid. Cancers, 2020, 12, 2275.	1.7	8
763	IGFBP7 activates retinoid acidâ€“induced responses in acute myeloid leukemia stem and progenitor cells. Blood Advances, 2020, 4, 6368-6383.	2.5	4
764	Second Primary Malignancy after Acute Promyelocytic Leukemia: A Population-Based Study. Cancers, 2020, 12, 3610.	1.7	7
765	Effect of daunorubicin on acute promyelocytic leukemia cells using nuclear magnetic resonance spectroscopy-based metabolomics. Environmental Toxicology and Pharmacology, 2020, 78, 103382.	2.0	3
766	Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization. Science China Life Sciences, 2020, 63, 1744-1754.	2.3	14
767	NLS-RARÎ± blocks cell differentiation by inhibiting the retinoic acid signalling pathway. Biochemical and Biophysical Research Communications, 2020, 528, 276-284.	1.0	1
768	Arsenic Exposure and Compromised Protein Quality Control. Chemical Research in Toxicology, 2020, 33, 1594-1604.	1.7	29

#	Article	IF	Citations
769	iRGD and TGN co-modified PAMAM for multi-targeted delivery of ATO to gliomas. Biochemical and Biophysical Research Communications, 2020, 527, 117-123.	1.0	29
770	Multiple roles of HOX proteins in Metastasis: Let me count the ways. Cancer and Metastasis Reviews, 2020, 39, 661-679.	2.7	19
771	The prognostic value of CD2, CD4, and HLA-DR expression and FLT3-ITD mutation in adult acute promyelocytic leukemia. Leukemia and Lymphoma, 2020, 61, 2482-2487.	0.6	4
772	RIG-I regulates myeloid differentiation by promoting TRIM25-mediated ISGylation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14395-14404.	3.3	25
773	ATO (Arsenic Trioxide) Effects on Promyelocytic Leukemia Nuclear Bodies Reveals Antiviral Intervention Capacity. Advanced Science, 2020, 7, 1902130.	5.6	9
774	Functionalisation and stabilisation of polymeric arsenical nanoparticles prepared by sequential reductive and radical cross-linking. Polymer Chemistry, 2020, 11, 2519-2531.	1.9	2
775	The Tripartite Nexus: Autophagy, Cancer, and Tripartite Motif-Containing Protein Family Members. Frontiers in Pharmacology, 2020, 11, 308.	1.6	37
776	Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2. Cancers, 2020, 12, 648.	1.7	9
777	NanoVar: accurate characterization of patientsâ€™ genomic structural variants using low-depth nanopore sequencing. Genome Biology, 2020, 21, 56.	3.8	73
778	Arsenic trioxide induces gasdermin E mediated pyroptosis in astroglioma cells. Translational Cancer Research, 2020, 9, 1926-1930.	0.4	8
779	Oxidative Stress in Cancer. Cancer Cell, 2020, 38, 167-197.	7.7	1,203
780	A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia. Journal of Molecular Medicine, 2020, 98, 1069-1091.	1.7	44
781	PML Nuclear Body Biogenesis, Carcinogenesis, and Targeted Therapy. Trends in Cancer, 2020, 6, 889-906.	3.8	33
782	Old dog, new trick: Trivalent arsenic as an immunomodulatory drug. British Journal of Pharmacology, 2020, 177, 2199-2214.	2.7	16
783	Polymorphisms in arsenic (+â€‰3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As2O3. Archives of Toxicology, 2020, 94, 1203-1213.	1.9	12
784	Current understanding of potential ecological risks of retinoic acids and their metabolites in aquatic environments. Environment International, 2020, 136, 105464.	4.8	23
785	Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis. Biomedicine and Pharmacotherapy, 2020, 125, 109878.	2.5	13
786	Interplay of Ubiquitin-Like Modifiers Following Arsenic Trioxide Treatment. Journal of Proteome Research, 2020, 19, 1999-2010.	1.8	4

#	Article	IF	Citations
787	Arsenic represses airway epithelial mucin expression by affecting retinoic acid signaling pathway. Toxicology and Applied Pharmacology, 2020, 394, 114959.	1.3	8
788	Follow-up and outcome of the twelve-year experience in adult patients with acute promyelocytic leukemia. Hematology, Transfusion and Cell Therapy, 2021, 43, 21-27.	0.1	2
789	Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets. , 2021, 220, 107722.		16
790	Small molecules regulating reactive oxygen species homeostasis for cancer therapy. Medicinal Research Reviews, 2021, 41, 342-394.	5.0	107
791	Retrospective analysis of data from 73 patients with childhood acute promyelocytic leukaemia receiving modified chemotherapy: a single-centre study. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1189-1201.	1.2	2
792	Traditional Chinese Medicine and orthopedic biomaterials: Host of opportunities from herbal extracts. Materials Science and Engineering C, 2021, 120, 111760.	3.8	18
793	Retinoic Acid Synthesis Deficiency Fosters the Generation of Polymorphonuclear Myeloid-Derived Suppressor Cells in Colorectal Cancer. Cancer Immunology Research, 2021, 9, 20-33.	1.6	15
794	Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia. Leukemia and Lymphoma, 2021, 62, 696-702.	0.6	6
795	Investigation of fibrinogen in early bleeding of patients with newly diagnosed acute promyelocytic leukemia. Platelets, 2021, 32, 677-683.	1.1	8
796	Characterizing therapeutic signatures of transcription factors in cancer by incorporating profiles in compound treated cells. Bioinformatics, 2021, 37, 1008-1014.	1.8	0
797	A PML/RARÎ± direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia. Blood, 2021, 137, 1503-1516.	0.6	47
798	Bronchoalveolar lavage fluid review in acute promyelocytic leukemia differentiation syndrome. Journal of Hematopathology, 2021, 14, 75-78.	0.2	0
799	History of Acute Promyelocytic Leukemia. Clinical Hematology International, 2021, 3, 142.	0.7	10
800	Rewiring Tumor Cell State in Cancer Therapy: Comment on â€˜9-cis-UAB30, a Novel Rexinoid Agonist, Decreases Tumorigenicity and Cancer Cell Stemness of Human Neuroblastoma Patient-Derived Xenograftsâ€™ by â€˜Elizabeth Beierle et al.â€™. Translational Oncology, 2021, 14, 100967.	1.7	0
801	All-Trans Retinoic Acid-Induced Ototoxicity during Chemotherapy in Pediatric Acute Promyelocytic Leukemia. Children, 2021, 8, 27.	0.6	1
802	Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	31
803	An Outcome Analysis of Childhood Acute Promyelocytic Leukemia Treated with Atra and Arsenic Trioxide, and Limited Dose Anthracycline. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 569-575.	0.3	4
805	Metal Complexes as Drugs and Therapeutic Agents. , 2021, , 680-705.		4

#	Article	IF	Citations
806	How Chinese Herbal Medicine Prevents Epidemics: From Ancient Pestilences to COVID-19 Pandemic. The American Journal of Chinese Medicine, 2021, 49, 1017-1044.	1.5	28
807	The Effects of Voriconazole on Metabolism of All-Trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia: A Case Report. Cureus, 2021, 13, e13337.	0.2	0
808	Applications of next-generation sequencing in hematologic malignancies. Human Immunology, 2021, 82, 859-870.	1.2	8
809	Endogenous and combination retinoids are active in myelomonocytic leukemias. Haematologica, 2021, 106, 1008-1021.	1.7	11
810	Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. Cancer Cell, 2021, 39, 225-239.e8.	7.7	125
813	OGP46 Induces Differentiation of Acute Myeloid Leukemia Cells via Different Optimal Signaling Pathways. Frontiers in Cell and Developmental Biology, 2021, 9, 652972.	1.8	5
814	Synthetic cyclopenta[b]indoles exhibit antineoplastic activity by targeting microtubule dynamics in acute myeloid leukemia cells. European Journal of Pharmacology, 2021, 894, 173853.	1.7	3
815	Critical regulatory levels in tumor differentiation: Signaling pathways, epigenetics and nonâ€coding transcripts. BioEssays, 2021, 43, 2000190.	1.2	0
816	Jiyuan Oridonin A Overcomes Differentiation Blockade in Acute Myeloid Leukemia Cells With MLL Rearrangements via Multiple Signaling Pathways. Frontiers in Oncology, 2021, 11, 659720.	1.3	9
817	Targeting Pin1 for Modulation of Cell Motility and Cancer Therapy. Biomedicines, 2021, 9, 359.	1.4	14
818	Perspectives on current survival and new developments in AML. Best Practice and Research in Clinical Haematology, 2021, 34, 101248.	0.7	15
819	Reducing FASN expression sensitizes acute myeloid leukemia cells to differentiation therapy. Cell Death and Differentiation, 2021, 28, 2465-2481.	5.0	30
820	Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol. British Journal of Clinical Pharmacology, 2021, 87, 4020-4026.	1.1	7
821	miR-139-5p Regulates the Proliferation of Acute Promyelocytic Leukemia Cells by Targeting MNT. Journal of Oncology, 2021, 2021, 1-9.	0.6	3
822	Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells. Acta Pharmacologica Sinica, 2021, 42, 832-842.	2.8	25
823	C/EBPÎ± is indispensable for PML/RARÎ±-mediated suppression of long non-coding RNA NEAT1 in acute promyelocytic leukemia cells. Aging, 2021, 13, 13179-13194.	1.4	1
824	Inhibition of mitochondrial complex III induces differentiation in acute myeloid leukemia. Biochemical and Biophysical Research Communications, 2021, 547, 162-168.	1.0	4
825	How I Treat Acute Promyelocytic Leukemia. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 286-292.	0.1	0

#	Article	IF	Citations
826	Current views on the genetic landscape and management of variant acute promyelocytic leukemia. Biomarker Research, 2021, 9, 33.	2.8	30
827	Absolute Circulating Leukemic Cells as a Risk Factor for Early Bleeding Events in Patients with Non-High-Risk Acute Promyelocytic Leukemia. Cancer Management and Research, 2021, Volume 13, 4135-4146.	0.9	2
828	Induced lineage promiscuity undermines the efficiency of all-trans-retinoid-acid-induced differentiation of acute myeloid leukemia. IScience, 2021, 24, 102410.	1.9	1
829	Liposome-Coated Arsenicâ€“Manganese Complex for Magnetic Resonance Imaging-Guided Synergistic Therapy Against Carcinoma. International Journal of Nanomedicine, 2021, Volume 16, 3775-3788.	3.3	14
830	Immunotherapeutic Potential of m6A-Modifiers and MicroRNAs in Controlling Acute Myeloid Leukaemia. Biomedicines, 2021, 9, 690.	1.4	18
831	Single-cell RNA sequencing of peripheral blood mononuclear cells from the patient with acute promyelocytic leukemia: a case study. Annals of Blood, 0, 6, 21-21.	0.4	0
832	Overview of Iraqi experience in management of acute promyelocytic leukemia. The Medical Journal of Basrah University, 2021, 39, 21-30.	0.1	0
834	Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide. Expert Review of Clinical Pharmacology, 2021, 14, 1173-1182.	1.3	2
835	Crosstalk between hnRNP K and SET in ATRAâ€induced differentiation in acute promyelocytic leukemia. FEBS Open Bio, 2021, 11, 2019-2032.	1.0	2
836	Risk factors of thrombosis in Chinese subjects with acute promyelocytic leukemia. Thrombosis Journal, 2021, 19, 42.	0.9	7
837	Gene Transcription as a Therapeutic Target in Leukemia. International Journal of Molecular Sciences, 2021, 22, 7340.	1.8	1
838	Arsenene Nanodots with Selective Killing Effects and their Lowâ€Dose Combination with ÃŸâ€Elemene for Cancer Therapy. Advanced Materials, 2021, 33, e2102054.	11.1	93
839	Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia. European Journal of Medicinal Chemistry, 2021, 220, 113451.	2.6	31
840	LncRNA KCNQ1OT1 activated by c-Myc promotes cell proliferation via interacting with FUS to stabilize MAP3K1 in acute promyelocytic leukemia. Cell Death and Disease, 2021, 12, 795.	2.7	14
841	Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia. Engineering, 2021, 7, 1354-1368.	3.2	0
842	Drug treatment options for acute promyelocytic leukemia. Expert Opinion on Pharmacotherapy, 2022, 23, 117-127.	0.9	9
843	Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms. Chinese Herbal Medicines, 2022, 14, 154-165.	1.2	4
844	Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors. Cell Death Discovery, 2021, 7, 259.	2.0	8

#	Article	IF	Citations
845	Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study. Journal of Clinical Oncology, 2021, 39, 3161-3170.	0.8	21
846	Importance of targeted therapies in acute myeloid leukemia. , 2021, , 107-133.		2
847	PML/RARÎ± Fusion Gene and Response to Retinoic Acid and Arsenic Trioxide Treatment. , 2021, , 363-386.		0
848	Genomic Landscape and Clonal Evolution of AML. Hematologic Malignancies, 2021, , 103-118.	0.2	0
849	Clinical Response to Traditional Chinese Herbs Containing Realgar (As2S2) is Related to DNA Methylation Patterns in Bone Marrow DNA from Patients with Myelodysplastic Syndrome with Multilineage Dysplasia. Cancer Management and Research, 2021, Volume 13, 55-63.	0.9	4
850	The impact of ICAM-1, CCL2 and TGM2 gene polymorphisms on differentiation syndrome in acute promyelocytic leukemia. BMC Cancer, 2021, 21, 46.	1.1	6
852	Sumoylation as a Signal for Polyubiquitylation and Proteasomal Degradation. Sub-Cellular Biochemistry, 2010, 54, 195-214.	1.0	55
853	Data Mining in Real-World Traditional Chinese Medicine Clinical Data Warehouse. , 2014, , 189-213.		3
854	Non-native Proteins as Newly-Identified Targets of Heavy Metals and Metalloids. , 2011, , 263-274.		15
855	Acute Myeloid Leukemia. , 2011, , 672-697.		3
856	Quantitative knowledge presentation models of traditional Chinese medicine (TCM): A review. Artificial Intelligence in Medicine, 2020, 103, 101810.	3.8	41
857	CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia. Bioscience Reports, 2020, 40, .	1.1	7
863	Bradycardia following retinoic acid differentiation syndrome in a patient with acute promyelocytic leukaemia. BMJ Case Reports, 2012, 2012, bcr0220125848-bcr0220125848.	0.2	5
864	Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden. BMJ Supportive and Palliative Care, 2020, , bmjspcare-2020-002281.	0.8	1
865	Sphingosine-1-Phosphate Receptor 3 Potentiates Inflammatory Programs in Normal and Leukemia Stem Cells to Promote Differentiation. Blood Cancer Discovery, 2021, 2, 32-53.	2.6	35
866	Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre. Singapore Medical Journal, 2014, 55, 443-447.	0.3	23
867	Arsenic Trioxide Induces Apoptosis in Human Platelets via C-Jun NH2-Terminal Kinase Activation. PLoS ONE, 2014, 9, e86445.	1.1	19
868	All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment. PLoS ONE, 2015, 10, e0127790.	1.1	54

#	Article	IF	Citations
869	Tetraarsenictetrasulfide and Arsenic Trioxide Exert Synergistic Effects on Induction of Apoptosis and Differentiation in Acute Promyelocytic Leukemia Cells. PLoS ONE, 2015, 10, e0130343.	1.1	16
870	Indole itself and its novel derivative affect PML cells proliferation via controlling the expression of cell cycle genes. Cellular and Molecular Biology, 2019, 65, 41.	0.3	4
871	Acute Myeloid Leukemia Acquiring Promyelocytic Leukemia-Retinoic Acid Receptor Alpha at Relapse. World Journal of Oncology, 2019, 10, 153-156.	0.6	1
872	Optimizing Growth Conditions for Digoxin Production in Digitalis lanata Ehrh. World Journal of Traditional Chinese Medicine, 2016, 2, 24-35.	0.9	3
874	Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia. Oncotarget, 2016, 7, 47319-47331.	0.8	6
875	C-Myc functions as a competing endogenous RNA in acute promyelocytic leukemia. Oncotarget, 2016, 7, 56422-56430.	0.8	13
876	Induction treatments for acute promyelocytic leukemia: a network meta-analysis. Oncotarget, 2016, 7, 71974-71986.	0.8	4
877	Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget, 2016, 7, 82504-82510.	0.8	64
878	Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6. Oncotarget, 2017, 8, 103087-103099.	0.8	16
879	Trisenox disrupts MDM2-DAXX-HAUSP complex and activates p53, cell cycle regulation and apoptosis in acute leukemia cells. Oncotarget, 2018, 9, 33138-33148.	0.8	9
880	Inhibition of adipose triglyceride lipase (ATGL) by the putative tumor suppressor G0S2 or a small molecule inhibitor attenuates the growth of cancer cells. Oncotarget, 2015, 6, 28282-28295.	0.8	75
881	MicroRNA-452 promotes stem-like cells of hepatocellular carcinoma by inhibiting Sox7 involving Wnt/Î²-catenin signaling pathway. Oncotarget, 2016, 7, 28000-28012.	0.8	62
882	Development of Pin1 Inhibitors and their Potential as Therapeutic Agents. Current Medicinal Chemistry, 2020, 27, 3314-3329.	1.2	14
883	Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects. Current Drug Metabolism, 2013, 14, 1029-1041.	0.7	22
884	Novel Mechanistic Insights into the Anti-cancer Mode of Arsenic Trioxide. Current Cancer Drug Targets, 2020, 20, 115-129.	0.8	8
885	The Antitumoral Activity of Zataria Multiflora Methanolic Extract on Acute Promyelocytic Leukemia Cell Line; NB4. Journal of Advances in Medical and Biomedical Research, 2018, 26, 43-47.	0.1	4
886	A Case of Therapy-related Myeloid Neoplasm after Successful Treatment of Acute Promyelocytic Leukemia. Laboratory Medicine Online, 2011, 1, 227.	0.0	1
889	Analysis of factors affecting hemorrhagic diathesis and overall survival in patients with acute promyelocytic leukemia. Korean Journal of Internal Medicine, 2015, 30, 884-890.	0.7	7

#	Article	IF	Citations
890	The effect of aqueous cinnamon extract on the apoptotic process in acute myeloid leukemia HL-60 cells. Advanced Biomedical Research, 2013, 2, 25.	0.2	14
891	From conventional therapy toward microRNA-based therapy in acute promyelocytic leukemia. Advanced Biomedical Research, 2016, 5, 187.	0.2	6
892	Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line. Cancer Research and Treatment, 2013, 45, 126-133.	1.3	8
893	Megadoses of Sodium Ascorbate Efficiently Kill HL60 Cells <i>in Vitro</i>: Comparison with Arsenic Trioxide. Journal of Cancer Therapy, 2013, 04, 1366-1372.	0.1	8
894	Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome. World Journal of Radiology, 2014, 6, 583.	0.5	27
895	Acute Promyelocytic Leukemia: A Model Disease for Targeted Cancer Therapy. , 0, , .		1
896	Acute Myeloid Leukemia Diagnosis in the 21st Century. Archives of Pathology and Laboratory Medicine, 2010, 134, 1427-1433.	1.2	54
897	Arsenic Trioxide Inhibits Cell Growth and Invasion via Down-Regulation of Skp2 in Pancreatic Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3805-3810.	0.5	24
898	Monensin may inhibit melanoma by regulating the selection between differentiation and stemness of melanoma stem cells. PeerJ, 2019, 7, e7354.	0.9	9
899	Inorganic substances and their uses in Nikolaos Myrepsosâ€™ Dynameron. Recent applications in modern therapy. Toxicology Reports, 2021, 8, 1792-1802.	1.6	1
900	Acute Promyelocytic Leukemia: Update on Risk Stratification and Treatment Practices. Cancer Treatment and Research, 2021, 181, 45-55.	0.2	2
901	All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Science Immunology, 2021, 6, .	5.6	24
902	Distinct Characteristics of Sweetâ€™s Syndrome of the Scrotum Caused by All-trans Retinoic Acid in a Patient with Acute Promyelocytic Leukemia. Case Reports in Oncology, 2021, 14, 1466-1474.	0.3	2
903	Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing. British Journal of Cancer, 2022, 126, 275-286.	2.9	6
904	Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia. Blood Advances, 2022, 6, 652-663.	2.5	4
905	miRâ€221/222 suppression induced by activation of the cAMP/PKA/CREB1 pathway is required for cAMPâ€induced bidirectional differentiation of glioma cells. FEBS Letters, 2021, 595, 2829-2843.	1.3	2
906	Disparity in Utilization of Multiagent Therapy for Acute Promyelocytic Leukemia in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 319-325.	0.2	2
908	Understanding Molecular Pathogenesis: The Biological Basis of Human Disease and Implications for Improved Treatment of Human Disease. , 2009, , 209-218.		0

#	Article	IF	Citations
909	Molecular Basis of Lymphoid and Myeloid Diseases. , 2009, , 265-290.		0
912	Understanding Molecular Pathogenesis. , 2010, , 143-152.		0
913	Nuclear Subdomains and Cancer. , 2011, , 1-58.		0
917	An exciting time to launch theWorld Journal of Hematology. World Journal of Hematology, 2012, 1, 1.	0.1	0
918	DNA Methylation in Acute Leukemia. , 0, , .		0
919	Leukemia Surveillance Counterpoint: Japan. , 2013, , 485-486.		0
920	Personalized Approach to Diagnosis and Treatment of Acute Myeloid Leukemia. , 2013, 03, .		0
922	PML/RAR_ Fusion Gene and Response to Retinoic Acid and Arsenic Trioxide Treatment. , 2013, , 313-336.		0
923	How to Teach the Topic of Acute Myelogenous Leukemia: Recommendations for Achieving Curricular Milestones. Journal of Leukemia (Los Angeles, Calif), 2014, 02, .	0.1	0
924	Pharmacogenomics in Molecular Oncology. , 2014, , 405-421.		0
925	PML/RARA as the Master Driver of APL Pathogenesis and Therapy Response. , 2015, , 461-475.		0
926	Pharmacogenetics and Antineoplastic Therapies. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 275-305.	0.6	0
927	Drug Resistance to Calicheamicin Conjugated Monoclonal Antibody Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 165-183.	0.1	0
928	Molekulare Grundlagen der malignen Transformation. , 2015, , 1-16.		0
929	Food as a drug. Oncoscience, 2015, 2, 801-802.	0.9	0
931	Cytokine Production and Human Cytomegalovirus Load in Allogeneic Hematopoietic Stem Cell Transplantation Outcome. International Journal of Immunotherapy and Cancer Research, 0, , 003-010.	0.4	0
932	Studies on Arsenic and Human Health. , 2017, , 37-66.		0
933	Retinoic Acid, All-trans Retinoic Acid (ATRA), and Tamibarotene. , 2017, , 183-211.		2

#	Article	IF	Citations
934	Akute myeloische LeukÃmie beim alten und geriatrischen Patienten. , 2017, , 1-16.		0
936	Acute Promyelocyte Leukemia in A Child Presented With Proptosis: A Case Report And Literature Review. IOSR Journal of Dental and Medical Sciences, 2017, 16, 29-33.	0.0	0
937	Arsenic trioxide nanoparticles inhibit acute promyelocytic leukemia cell proliferation and induce apoptosis via PTEN/AKT signalling pathway. Biomedical Research (Aligarh, India), 2018, 29, .	0.1	2
938	Akute myeloische LeukÃmie beim alten und geriatrischen Patienten. , 2018, , 213-228.		0
939	Automation In High Throughput/Content Screening For Cancer Stem Cell Drug Discovery. , 2018, , .		0
941	Immune Thrombocytopenia: Are We Stuck in the Mud or Is There Light at the End of the Tunnel?. Clinical Hematology International, 2019, 1, 173-179.	0.7	0
942	DetecciÃ³n del gen fusiÃ³n PML-RARÎ± en pacientes colombianos con leucemia mieloide aguda. CES Medicina, 2019, 33, 88-99.	0.1	0
943	Applications of Different Biomarkers in the Diagnosis of Drug-induced Liver Injury. Open Biomarkers Journal, 2019, 9, 55-61.	0.1	0
946	Coexistence of Acute Promyelocytic Leukemia and Primary Plasma Cell Leukemia: Careful Consideration in Diagnosis. Annals of Laboratory Medicine, 2022, 42, 278-281.	1.2	1
947	PML nuclear body biogenesis and oligomerization-driven leukemogenesis. Blood Science, 2020, 2, 7-10.	0.4	1
948	Editorial Comment On: Prognostic Implication of Body Mass Index on Survival Outcomes in Surgically-Treated Non-metastatic Renal Cell Carcinoma: A Single Institutional, Retrospective Analysis of a Large Cohort. Annals of Surgical Oncology, 2020, 27, 2137-2138.	0.7	0
949	Successful treatment of relapsed acute promyelocytic leukemia with arsenic trioxide in a hemodialysis-dependent patient: A case report. World Journal of Clinical Cases, 2020, 8, 5347-5352.	0.3	0
950	Effects of arsenic trioxide, all-trans-retinoic acid and dexamethasone on NB4 cell line. DARU, Journal of Pharmaceutical Sciences, 2010, 18, 303-9.	0.9	5
951	Cytogenetic and FMS-like tyrosine kinase 3 mutation analyses in acute promyelocytic leukemia patients. Iranian Biomedical Journal, 2012, 16, 10-7.	0.4	2
952	Detection of retinoid receptors in non-neoplastic canine lymph nodes and in lymphoma. Canadian Veterinary Journal, 2014, 55, 1219-24.	0.0	3
953	Construction of protein profile classification model and screening of proteomic signature of acute leukemia. International Journal of Clinical and Experimental Pathology, 2014, 7, 5569-81.	0.5	9
954	Reactive oxygen species regulate the differentiation of acute promyelocytic leukemia cells through HMGB1-mediated autophagy. American Journal of Cancer Research, 2015, 5, 714-25.	1.4	17
955	Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biology and Medicine, 2015, 12, 316-27.	1.4	5

#	Article	IF	Citations
956	Development of Reverse Transcription Loop-Mediated Isothermal Amplification for Simple and Rapid Detection of Î± mRNA. Yonago Acta Medica, 2016, 59, 262-269.	0.3	7
958	Arsenic Trioxide and Thalidomide Combination Induces Autophagy Along with Apoptosis in Acute Myeloid Cell Lines. Cell Journal, 2020, 22, 193-202.	0.2	4
965	Effect of arsenic trioxide on cervical cancer and its mechanisms. Experimental and Therapeutic Medicine, 2020, 20, 169.	0.8	3
966	Cryptic t(15;17) acute promyelocytic leukemia with a karyotype of add(11)(p15) and t(13,20)- A case report with a literature review. Bosnian Journal of Basic Medical Sciences, 2021, 21, 246-251.	0.6	0
967	Betulinic acid exerts antitumor effects on acute promyelocytic leukemia cells possibly via hTERT downregulation. Gene Reports, 2022, 26, 101435.	0.4	1
968	Deconvolution of Bulk Gene Expression Profiles with Single-Cell Transcriptomics to Develop a Cell Type Composition-Based Prognostic Model for Acute Myeloid Leukemia. Frontiers in Cell and Developmental Biology, 2021, 9, 762260.	1.8	5
969	STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, 2022, 40, 438-452.	1.2	6
970	The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia. Frontiers in Cell and Developmental Biology, 2021, 9, 764698.	1.8	21
971	Predictive factors for differentiating thrombohemorrhagic disorders in high-risk acute promyelocytic leukemia. Thrombosis Research, 2022, 210, 33-41.	0.8	6
972	Effect of arsenic trioxide on cervical cancer and its mechanisms. Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	7
973	Cryptic t(15;17) acute promyelocytic leukemia with a karyotype of add(11)(p15) and t(13,20)- A case report with a literature review. Bosnian Journal of Basic Medical Sciences, 2021, 21, 246-251.	0.6	1
974	Outcome and complications of pediatric acute promyelocytic leukemia in Bangladesh. Pediatric Hematology and Oncology, 2022, , 1-12.	0.3	2
975	Gallium (III) Complexes in Cancer Chemotherapy. European Journal of Inorganic Chemistry, 2022, 2022, .	1.0	20
976	TP53 inhibitor PFTÎ± increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells. FEBS Open Bio, 2022, 12, 616-626.	1.0	2
978	Early mortality and overall survival in acute promyelocytic leukemia â€“ a single-center experience. Makedonsko Farmacevtski Bilten, 2022, 67, 55-66.	0.0	0
979	Effect of Therapeutically Related Drugs on Coagulation-Anticoagulation Balance in Acute Promyelocytic Leukemia. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210801.	0.7	0
980	C11orf21, a novel RUNX1 target gene, is down-regulated by RUNX1-ETO. BBA Advances, 2022, 2, 100047.	0.7	2
981	Cooperative coordination-mediated multi-component self-assembly of â€œall-in-oneâ€•nanospike theranostic nano-platform for MRI-guided synergistic therapy against breast cancer. Acta Pharmaceutica Sinica B, 2022, 12, 3710-3725.	5.7	14

#	Article	IF	Citations
982	Genetic analysis and clinical significance of a rare t(1;12)(q21;p13) in a patient with highâ€risk myelodysplastic syndrome. Molecular Genetics & Genomic Medicine, 2022, , e1893.	0.6	1
983	Systematic Analysis of Molecular Characterization and Clinical Relevance of Liquidâ€“Liquid Phase Separation Regulators in Digestive System Neoplasms. Frontiers in Cell and Developmental Biology, 2021, 9, 820174.	1.8	4
984	Research Progress of Natural Small-Molecule Compounds Related to Tumor Differentiation. Molecules, 2022, 27, 2128.	1.7	3
985	Developmental arsenic exposure impairs cognition, directly targets DNMT3A, and reduces DNA methylation. EMBO Reports, 2022, 23, e54147.	2.0	5
986	A novel coexistence of tetrasomy 8 and FLT3-ITD along with variant 3 way translocation t(4;17;15) in acute promyelocytic leukemia: Case study and literature review. Cancer Genetics, 2022, 262-263, 111-117.	0.2	0
987	The Effects of Sesquiterpene Lactones on the Differentiation of Human or Animal Cells Cultured In-Vitro: A Critical Systematic Review. Frontiers in Pharmacology, 2022, 13, 862446.	1.6	3
988	Bclâ€2 hijacks the arsenic trioxide resistance in SHâ€SY5Y cells. Journal of Cellular and Molecular Medicine, 2022, 26, 563-569.	1.6	7
989	Inhibition of pyrimidine biosynthesis by strobilurin derivatives induces differentiation of acute myeloid leukemia cells. Leukemia and Lymphoma, 2022, 63, 1202-1210.	0.6	3
990	Histone Deacetylase Inhibitor I3 Induces Differentiation of Acute Myeloid Leukemia Cells with T(8;21) or MLL Gene Translocation and Leukemic Stem-Like Cells. SSRN Electronic Journal, 0, , .	0.4	0
991	The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells. Frontiers in Oncology, 2022, 12, 855570.	1.3	1
992	Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy. AAPS PharmSciTech, 2022, 23, 111.	1.5	4
993	Acute promyelocytic leukemia: pathophysiology and clinical results update. , 0, , 131-140.		0
998	A hypogranular variant of acute promyelocytic leukaemia showing a heterogenic immunophenotype with CD34, CD2, HLA-DR positivity: a case report and review of the literature. Acta Clinica Belgica, 2012, 67, 34-8.	0.5	2
1006	Arsenic trioxide induces proteasome dependent TBLR1-RARÎ± degradation to improve leukemia eradication through cell differentiation enhancement. Journal of Cancer, 2022, 13, 2301-2311.	1.2	0
1007	Atypical morphology and aberrant immunophenotypic expression: A diagnostic dilemma in acute promyelocytic leukemia. Journal of Applied Hematology, 2022, 13, 63.	0.1	1
1008	The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene Rearrangements via Epigenetic Modification. Frontiers in Pharmacology, 2022, 13, 876076.	1.6	5
1009	Do high-mobility group box 1 gene polymorphisms affect the incidence of differentiation syndrome in acute promyelocytic leukemia?. Molecular Biology Reports, 2022, , 1.	1.0	0
1010	G-CSF upregulates the expression of aquaporin-9 through CEBPB to enhance the cytotoxic activity of arsenic trioxide to acute myeloid leukemia cells. Cancer Cell International, 2022, 22, 195.	1.8	4

#	Article	IF	Citations
1011	Nanodiamonds Improve Arsenic Trioxide Treatment of Liver Tumor by Inhibiting Metastasis in Multiple Organs. SSRN Electronic Journal, 0, , .	0.4	0
1012	A Scientometric and Visualization Analysis of Arsenic for Acute Promyelocytic Leukemia Studies. SSRN Electronic Journal, 0, , .	0.4	0
1013	Recurrent noncoding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia. Blood, 2022, 140, 1132-1144.	0.6	7
1014	The immunomodulatory role of all-trans retinoic acid in tumor microenvironment. Clinical and Experimental Medicine, 2023, 23, 591-606.	1.9	4
1015	A tubulin binding molecule drives differentiation of acute myeloid leukemia cells. IScience, 2022, 25, 104787.	1.9	3
1016	Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia. Korean Journal of Internal Medicine, 2022, 37, 841-850.	0.7	0
1017	A scientometric and visualization analysis of studies on arsenic for acute promyelocytic leukemia. European Journal of Integrative Medicine, 2022, , 102162.	0.8	0
1018	Arsenic trioxide-loaded nanoparticles enhance the chemosensitivity of gemcitabine in pancreatic cancer via the reversal of pancreatic stellate cell desmoplasia by targeting the AP4/galectin-1 pathway. Biomaterials Science, 2022, 10, 5989-6002.	2.6	8
1020	Engaging plasticity: Differentiation therapy in solid tumors. Frontiers in Pharmacology, 0, 13, .	1.6	13
1021	Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies. Pharmacological Research, 2022, 184, 106456.	3.1	13
1022	ATRA-induced bradycardia in a case of acute promyelocytic leukemia: A case report. Journal of Family Medicine and Primary Care, 2022, 11, 3999.	0.3	0
1023	Histone Deacetylase Inhibitor I3 Induces the Differentiation of Acute Myeloid Leukemia Cells with t (8;) Tj ETQq1 1 0.784314 rgBT /Over	0.6	2
1024	How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy. Journal of Molecular Endocrinology, 2022, 69, T69-T83.	1.1	6
1025	The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases. Pharmaceutics, 2022, 14, 1945.	2.0	4
1026	Jiyuan oridonin A induces differentiation of acute myeloid leukemia cells including leukemic stem-like cells. Frontiers in Pharmacology, 0, 13, .	1.6	0
1027	Subcellular Partitioning of Arsenic Trioxide Revealed by Label-Free Imaging. Analytical Chemistry, 2022, 94, 13889-13896.	3.2	2
1028	Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies. Blood Cancer Journal, 2022, 12, .	2.8	2
1029	HOXA9 has the hallmarks of a biological switch with implications in blood cancers. Nature Communications, 2022, 13, .	5.8	4

#	Article	IF	Citations
1030	Sequence-specific amperometric detection based on a double-probe mode and enzyme-mediated multiple signal electrocatalysis for the double-stranded DNA of PML/RARÎ±-related fusion gene. Analytica Chimica Acta, 2022, 1231, 340436.	2.6	2
1031	Alterations induced by the PML-RARÎ± oncogene revealed by Image Cross-Correlation Spectroscopy. Biophysical Journal, 2022, , .	0.2	1
1032	Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARÎ±. Acta Pharmacologica Sinica, 2023, 44, 822-831.	2.8	2
1033	Non-leukemic presentation of acute promyelocytic leukemia as a testicular mass with associated non-canonical FLT3 mutation. Leukemia and Lymphoma, 2022, 63, 3493-3496.	0.6	0
1035	Chemoproteomic Approach for the Quantitative Identification of Arsenic-Binding Proteins. Chemical Research in Toxicology, 2022, 35, 2145-2151.	1.7	1
1036	Nanodiamonds improve arsenic trioxide treatment of liver tumor by inhibiting metastasis in multiple organs. Nano Today, 2022, 47, 101649.	6.2	3
1037	Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia. Experimental Hematology and Oncology, 2022, 11, .	2.0	4
1038	AS1411aptamer conjugated liposomes for targeted delivery of arsenic trioxide in mouse xenograft model of melanoma cancer. , 2022, , 213194.		0
1040	Lipid-polymer hybrid nanoparticle with cell-distinct drug release for treatment of stemness-derived resistant tumor. Acta Pharmaceutica Sinica B, 2023, 13, 1262-1273.	5.7	8
1041	Targeting emerging cancer hallmarks by transition metal complexes: Cancer stem cells and tumor microbiome. Part I. Coordination Chemistry Reviews, 2023, 477, 214923.	9.5	2
1042	Development of Acute Promyelocytic Leukemia in a Patient with Granulomatosis with Polyangiitis: A Case Report. Tohoku Journal of Experimental Medicine, 2022, , .	0.5	2
1044	APL: Nemo finds its sea anemone. Blood, 2022, 140, 2311-2312.	0.6	1
1045	Cell of Origin of Brain and Spinal Cord Tumors. Advances in Experimental Medicine and Biology, 2023, , 85-101.	0.8	0
1046	At What Point Are Long-Term (>5 Years) Survivors of APL Safe? A Study from the SEER Database. Cancers, 2023, 15, 575.	1.7	3
1048	Breast Cancer and Arsenic Anticancer Effects: Systematic Review of the Experimental Data from In Vitro Studies. BioMed Research International, 2022, 2022, 1-16.	0.9	0
1049	The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA. Journal of Cell Biology, 2023, 222, .	2.3	5
1050	Roles of PADI4 in the expression of cytokines involved in inflammation and adhesion in differentiated NB4 cells treated with ATRA. Experimental and Therapeutic Medicine, 2023, 25, .	0.8	0
1051	Pharmaceutical/Clinical Strategies in the Treatment of Acute Promyelocytic Leukemia: All-Trans Retinoic Acid Encapsulation by Spray-Drying Technology as an Innovative Approachâ€“Comprehensive Overview. Pharmaceuticals, 2023, 16, 180.	1.7	0

#	Article	IF	Citations
1052	Myeloid Maturity: ATRA to Enhance Antiâ€“PD-1?. Clinical Cancer Research, 2023, 29, 1167-1169.	3.2	1
1054	Potential of natural products in combination with arsenic trioxide: Investigating cardioprotective effects and mechanisms. Biomedicine and Pharmacotherapy, 2023, 162, 114464.	2.5	4
1055	Chemotherapy-free treatment for acute promyelocytic leukemia: the pediatric view of a revolutionary tale. Frontiers in Oncology, 0, 13, .	1.3	1
1059	Microbial isolation and characterization of arsenic degrading microbes from soil and its RAPD analysis for bioremediation. Biomedical and Biotechnology Research Journal, 2023, 7, 93.	0.3	0
1060	Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	4
1061	Ferroptosis-inducing inorganic arsenic(II) sulfide nanocrystals enhance immune activation. Nano Research, 2023, 16, 9760-9767.	5.8	1
1062	Influence of cytokines on early death and coagulopathy in newly diagnosed patients with acute promyelocytic leukemia. Frontiers in Immunology, 0, 14, .	2.2	0
1063	Epigenetic regulation by ASXL1 in myeloid malignancies. International Journal of Hematology, 2023, 117, 791-806.	0.7	4
1064	Extirpating the cancer stem cell hydra: Differentiation therapy and Hyperthermia therapy for targeting the cancer stem cell hierarchy. Clinical and Experimental Medicine, 0, , .	1.9	0
1077	An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications. Cell Death Discovery, 2023, 9, .	2.0	6
1084	Unique opportunities of metal scaffolds in drug design. , 2023, , 875-899.		0
1088	Management of Relapsed Acute Promyelocytic Leukemia and the Role of Hematopoietic Stem Cell Transplantation. , 2023, , 251-254.		0
1096	Childhood Acute Promyelocytic Leukemia. , 2023, , .		0